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| Abstract
Dilated Cardiomyopathy (DCM) is frequently leading to heart failure. Familial analysis revealed
30% - 60 % of cases to be of genetic cause, predominantly occurring in genes encoding for structural
proteins. The underlying mechanisms and signalling events that translate DCM causing mutations
into the clinical phenotype are poorly understood. Previously, our group identified the Core-
Binding Factor β (CBFβ) to be an essential factor for maintaining the sarcomeric Z-disc structure
of the heart muscle. CBFβ is mainly located in the sarcomere and is retained in the cytoplasm via
the interaction with Filamin A (FLNA). However it is hypothesized that under stress conditions,
CBFβ is translocated to the nucleus, where it regulates the expression of several genes. To analyze
the contribution of FLNA to the development of heart failure we created a transient and a stable
loss-of-function model of FLNA in zebrafish.
FLNA transient knockdown (MO-flna) resulted in systolic dysfunction, defects in re-absorption of
cardiac matrix, a dilated atrium, blood regurgitation and maturation defects shown by uncompleted
heart looping. We observed a significantly reduced heart rate (MO-control vs MO-flna; mean±SD:
148±6.9 vs 108±25.1 beats/min, respectively; p<0.05) and fractional shortening (MO-control vs
MO-flna; mean±SD: 64.7±4.0 vs 19.3±10.8 beats/min, respectively; p<0.0001). We further estab-
lished the CRISPR-CAS9 mediated FLNA stable knockout (FLNA KO). Indeed, in F0 embryos
we observed a significantly reduced heart rate (wildtype vs FLNA KO; mean±SD: 144±17.6 vs
106±12.3 beats/min, respectively; p<0.0001) and fractional shortening (wildtype vs FLNA KO;
mean±SD: 64±8.9 % vs 43±8.8 %, respectively; p<0.0001), as observed for the FLNA knockdown.
F0 mosaic embryos were grown to adulthood and outcrossed with wildtype fish. Two FLNA KO
lines (with a predicted stop codon on flna exon 4) were selected for propagation. Heterozygous
adults from both lines showed a significantly reduced ejection fraction (wildtype vs FLNA KO;
mean±SD: 62±6.9 % vs 41±12.2 %, respectively; p<0.01) and increased ventilation frequency
(wildtype vs FLNA KO; mean±SD: 7±4.2 vs 15±7.0 buccal movements, respectively; p<0.001).
Compound heterozygous, with both lines mutations, developed a pericardial edema with a dilated
heart, stressing the potential role of FLNA in maintaining heart function. Homozygous embryos
from one of the lines, did not show a heart failure phenotype. In accordance, flnb was shown to be
up-regulated in FLNA KO adults, illustrating possible compensatory mechanisms activation. In
regard to CBFβ translocation mechanism, for the first time, β-adrenergic stress was identified as
a trigger for CBFβ translocation to the nucleus.
In conclusion, FLNA knockdown and knockout in zebrafish leads to a heart failure phenotype.
By deeply investigating FLNA regulation (such as cleavage, phosphorylation, response to external
cellular stress, etc) and its interacting partners (such as CBFβ), we will further our understanding
of the genetic pathogenic pathways involved in heart failure.
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| Zusammenfassung
Dilatative Kardiomyopathie (DCM) führt häufig zu Herzinsuffizienz. In familiären Untersuchun-
gen wurde festgestellt, dass 30 % - 60 % der Kardiomyopathien genetische Ursachen haben, die
überwiegend in den Genen, für Strukturproteine kodierend, vorkommen. Die zugrundeliegenden
Mechanismen, sowie Signalkaskaden, die dazu führen, dass DCM-assoziierte Mutationen zu einem
klinischen Phänotyp führen, sind noch nicht ausreichend untersucht. In vorangegangenen Studien
hat unsere Arbeitsgruppe den Core-Binding Factor β (CBFβ) als möglichen essentiellen Faktor
identifiziert, um die sarkomerische Z-Disk-Struktur im Herzmuskel aufrecht erhalten zu können.
CBFβ ist im Sarkomer lokalisiert und wird durch die Interaktion mit Filamin A (FLNA) im Zy-
toplasma gehalten. Allerdings wird angenommen, dass unter Stressbedingungen CBFβ in den
Nukleus transportiert wird und dort die Genexpression verschiedener Zielgene reguliert. Um die
Rolle von FLNA in der Entwicklung von Herzinsuffizienz zu analysieren, wurde ein stabiles und
transientes loss-of-function Modell in Zebrabärblingen etabliert.
Der transiente FLNA knockdown (MO-flna) zeigt eine systolische Dysfunktion, Defekte in der Re-
absorption der kardialen Matrix, einem dilatiertem Atrium, Blutrückfluss, sowie Defekte in der
Herzentwicklung, welches sich durch eine unvollständig ausgebildete Herzschleife zeigt. Wir kon-
nten eine reduzierte Herzfrequenz beobachten (MO-control vs MO-flna; Mittelwert±SD: 148±6.9
vs 108±25.1 Schläge/min; p<0.05) sowie eine veränderte linksventrikuläre Verkürzungsfraktion
(MO-control vs MO-flna; Mittelwert±SD: 64.7 ±4.0 vs 19.3±10.8 Schläge/min; p<0.0001). Des
Weiteren wurde eine stabile FLNA CRISPR-CAS9 knockout Mutante (FLNA KO) etabliert, welche
im Einklang mit der FLNA knockdown Mutante steht und für die F0 Embryonen eine signifikant re-
duzierte Herzfrequenz (Wildtyp vs FLNA KO; Mittelwert±SD: 144±17.6 vs 106±12.3 Schläge/min;
p<0.0001) sowie linksventrikuläre Verkürzungsfraktion (Wildtyp vs FLNA KO; Mittelwert±SD:
64±8.9 % vs 43±8.8 %; p<0.0001) zeigten. F0 Mosaik Embryonen wurden zu adulten Zebrabär-
blingen herangezüchtet und mit einer Wildtyplinie ausgekreuzt. Zwei der FLNA KO Linien (mit
einem Stopp Kodon ins flna Exon 4) wurden zur Fortpflanzung ausgewählt, um die Linie zu
erhalten. Heterozygote adulte Fische von beiden Linien zeigten eine signifikant reduzierte Ejek-
tionsfraktion (Wildtyp vs FLNA KO; Mittelwert±SD: 62±6.9 % vs 41±12.2 %; p<0.01) und eine
erhöhte Atemfrequenz (Wildtyp vs FLNA KO; Mittelwert±SD: 7±4.2 vs 15±7.0 Mundöffnun-
gen; p<0.001). Compound-Heterozygote Fische, mit Mutationen beider Linien, entwickelten ein
perikardiales Ödem mit Herzdilatation, welches die Rolle von FLNA in der Herzfunktion unter-
malt. Auffällig ist, dass die homozygoten Embryonen einer Linie den Phänotyp einer Herzinsuf-
fizienz nicht zeigten. In Übereinstimmung damit, wurde eine Hochregulation von flnb in FLNA
KO adulten Fischen gezeigt, was eine mögliche Aktivierung von Kompensations-mechanismen zeigt.
Abschließend wurde in Hinblick auf den CBFβ Translokationsmechanismus, adrenerger Stress zum
ersten Mal als ein Auslöser für CBFβ Translokation in den Nukleus identifiziert.
Zusammenfassend führt der FLNA knockdown und knockout im Zebrabärbling zu einem Phänotyp
der Herzinsuffizienz. Bei weiteren Untersuchungen in Hinblick auf Regulationsmechanismen von
FLNA (wie Proteinspaltung, Phosphorylierung, Stressantwort auf extrazelluläre Einflüsse etc.) und
dessen Interaktionspartnern (wie CBFβ) werden wir unser Verständnis von genetisch pathogenen
Reaktionswegen, die in die Herzinsuffizienz Enwicklung involviert sind, vertiefen.
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1 | Introduction
1.1 Cardiomyopathies
Heart failure (HF) affects 40 million people worldwide, with an increasing prevalence due to the age-
ing population (Morales and Hershberger, 2017; Czepluch, Wollnik, and Hasenfuß, 2018). Defined
as an insufficient cardiac output for appropriate end-organ perfusion, HF mortality rates exceed
40% at 5-year follow-up (Cahill, Ashrafian, and Watkins, 2013; Hobbs et al., 2007). HF strongly re-
duces the quality of life by affecting exercise tolerance and multi-organ function (Czepluch, Wollnik,
and Hasenfuß, 2018). Furthermore, HF itself represent the final phenotype of multiple pathways
derived from genetic and/or environmental influences.
Genetic contribution to heart failure is very complex and ranges from monogenic HF syndromes,
with high penetrance, to less penetrant and cumulative genetic variants. Cardiomyopathies can
derive from such genetic alterations.
According to the American Heart Association (AHA), "cardiomyopathies are a heterogeneous group
of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually
(but not invariably) exhibit inappropriate ventricular hypertrophy or dilation and are due to a
variety of causes that frequently are genetic. Cardiomyopathies either are confined to the heart
or are part of generalized systemic disorders, often leading to cardiovascular death or progressive
heart failure-related disability" (Maron et al., 2006).
Cardiomyopathies can be classified as primary (the patient does not have other conditions that lead
to a weakened myocardium) or secondary (if the myocardium is affected as a result of a systemic
or multiple organ disease). Furthermore, according to AHA, primary cardiomyopathies are divided
into three categories: genetic, mixed or acquired (Figure 1.1) (Maron et al., 2006).
Hypertrophic cardiomyopathy (HCM) is the most common primary genetic cardiomyopathy, with
a prevalence of 1 in 500 in the general population (Bonow, 2017). HCM is one of the most frequent
causes of sudden cardiac death in young and asymptomatic athletes (Maron, Pelliccia, and Spirito,
1995). In its typical form, it is characterized by a disproportional thickening of the ventricular
septum relative to the ventricle free wall (Figure 1.2) due to massive myocardial hypertrophy.
Patients with HCM often exhibit a reduced stroke volume due to impaired diastolic filling as a
consequence of reduced chamber size and compliance of the hypertrophied left ventricle. HCM
arises from autosomal dominant mutations, mainly in genes such as β myosin heavy chain (MYH),
cardiac troponin-T (TNNT), α-tropomyosin (TPM1) and myosin binding protein C (MYBPC)
(Aster, 2014).
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Figure 1.1: Classification of primary cardiomyopathies. Adapted from American Heart Association
Scientific Statement, Maron et al., 2006.
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Dilated cardiomyopathy (DCM) with a prevalence of 1:250 (Hershberger, Hedges, and Morales,
2013), is one of the most frequent causes for heart failure (Mestroni et al., 2014) and heart trans-
plantation at young age (Towbin et al., 2006). This disease is commonly characterized by pro-
gressive signs and symptoms of heart failure with systolic contractile dysfunction and cardiac
dilation (Figure 1.2). Patients are affected with cardiac stress caused by volume overload and high
end-diastolic pressure that results in reduced left ventricular ejection fraction (which translates to
decreased cardiac output). DCM is a multifactorial disease that can arise from genetic mutations,
myocarditis, chronic alcohol consumption, iron overload, among others. However, familial analysis
revealed that 30% to 50% of DCM are familial cases, with mutations occurring in a wide variety
of genes (from cytoskeleton to sarcolemma and nuclear envelop genes; Aster, 2014; Haas et al.,
2015). Nevertheless, in most cases the family size is too small to draw conclusions on heritage of
genetic variants. The underlying mechanisms and signalling events that translate DCM causing
mutations into the clinical phenotype are poorly understood.
Figure 1.2: Morphology of the most common primary cardiomyopathies. Most left is shown a
normal heart with represented right atrium (RA), right ventricle (RV), left atrium (LA) and left
ventricle (LV). Adapted from Genetische Diagnostik von Kardiomyopathien, Meder, 2017.
Other cardiomyopathies have been reported such as restrictive cardiomyopathy (RCM, Figure 1.2,
Aster, 2014), Arrhythmogenic Right Ventricle Cardiomyopathy (ARVC, Aster, 2014) and Left
Ventricular Non-Compaction (LVNC, Sedaghat-Hamedani et al., 2017) but with a much lower
prevalence in the general population.
Nearly 100 genes were associated with primary cardiomyopathies (Czepluch, Wollnik, and Hasen-
fuß, 2018). However, further research is needed to enlighten the mechanisms leading to the genetic
and phenotypic heterogeneity observed. Different variants within an individual gene can produce
contrasting cardiomyopathies and, on the contrary, different genetic mutations can lead to the
same cardiomyopathy. Furthermore, even within the same family, penetrance and expressivity
vary greatly, suggesting that multiple factors (such as genetic, epigenetic or environmental mod-
ifiers) contribute to the phenotype. Future research should be directed to identify pathogenic
mutations and variants, as well as defining the cellular and molecular mechanisms of genetic car-
diomyopathies. In this setting, understanding the contribution of multiple genes to a phenotype,
will allow targeted genetic testing of families, enabling early risk stratification and treatment before
cardiac decompensation or remodelling has occurred.
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1.2 Zebrafish in cardiovascular research
Since George Streisinger’s initial use of zebrafish in the early nineteens, zebrafish has been de-
veloped into a widely used model organism (Grunwald and Streisinger, 1992). Zebrafish possess
several advantages, such as very fast development, with most of organ primordia formed at 24
hours post-fertilization (hpf), translucent embryos, high egg abundance, small-sized embryos and
established pipelines of high-throughput molecular and drug screening (Poon and Brand, 2013).
It is an appealing model in cardiovascular research, given the high homology with humans [82% of
human disease-related genes listed in the Online Mendelian Inheritance in Man (OMIM) have at
least one orthologue in zebrafish, Howe et al., 2013]. The genetic pathways of heart development
are highly conserved between humans and zebrafish (Poon and Brand, 2013).
In the teleost fish, cardiac progenitors are specified at 5 hours post-fertilization (hpf, Figure 1.3 -
A). At 22 hpf, a cardiac cone is formed by the fusion of the bilateral heart fields. This cone extends
anteriorly and is reshaped into a primitive heart tube. By 24 hpf, the linear heart tube has an outer
myocardial and an inner myocardial layer, separated by "cardiac jelly" (the extracellular matrix).
At this point, the heart tube exhibits peristaltic contractile movements (Figure 1.3 - B). At 33
hpf, the heart tube acquires an S-shaped configuration by looping of the chambers. At 36 hpf, the
onset of the cardiac conduction system is outlined by the change in the slow peristaltic contractions
to a sequential chamber contraction (Figure 1.3 - C). At 37 hpf, the atrioventricular myocardium
undergoes a genetic identity shift, which triggers endocardial cell morphology changes. By 48 hpf,
the ventricular chambers balloons, displaying an outer curvature with big elongated myocardial
cells that are able to conduct electrical activity thrice as fast than cells in the inner curvature
(Figure 1.3 - D). At 72 hpf, the endocardial cells form the primitive valve leaflets, which block the
retrograde blood flow from the ventricle to the atrium (Figure 1.3 - E).
In an adult zebrafish heart, the atrium only has a thin layer of myocardial cells, whereas the
ventricle has trabeculae that thickens its walls (Figure 1.3 - F). The pacemaker site is located at
a ring-like structure, at the border between the sinus venosus and the atrium (Poon and Brand,
2013, Asnani and Peterson, 2014, Bakkers, 2011).
Zebrafish is also a relevant model in cardiomyopathy research (Asnani and Peterson, 2014). Mu-
tants like silent heart (tnnt2 gene disruption, Chen et al., 1996; Sehnert et al., 2002; Stainier et al.,
1996) and pickwickm171 (ttn truncating variant, Driever et al., 1996; Xu et al., 2002) have shown
that parallels can be drawn between genes relevant for primary cardiomyopathies in humans and
zebrafish (Vogel et al., 2009). Furthermore, JunB is a transcriptional factor responsible for the
activation of core-binding factor β (cbfβ) gene transcription in the heart and skeletal muscle cells.
JunB and CBFβ have been correlated with heart failure in zebrafish (Meder et al., 2010).
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Figure 1.3: Stages of cardiac development in zebrafish. A - at 5 hours post-fertilization (hpf),
the cardiac progenitor cells are located bilaterally in the lateral marginal zone. Atrial progenitor
cells (pink) are located more ventral than the ventricle progenitor cells (light blue), cardiogenic
differentiation is initiated in the future ventricle myocardial cells by the expression of cardiac
myosins. B - at 28 hpf, the linear heart tube has formed. C - new cardiomyocytes are added
to this region (purple gradient). At 36 hpf, cardiac looping has started, with a displacement
of the ventricle towards the mid-line and the constriction at the position of the atrioventricular
canal. D - the heart tube continues to loop and forms an S-shaped loop. Ellipsoid extracardiac
pro-epicardial cells (brown) are located near the atrioventricular canal (yellow), from where they
start to cover the myocardium with an epicardial layer. The pacemaker is present in the inner
curvature of the atrium near the venous pole (green). Adapted from Bakkers, 2011. E - cross-
section of the embryonic heart with 3 to 5 days post-fertilization (dpf). BV - bulboventricular;
AV - atrioventricular. Adapted from Brown et al., 2016. F - schematic representation of adult
zebrafish heart anatomy. BV - bulboventricular; AV - atrioventricular. Adapted from Poon and
Brand, 2013.
11
CHAPTER 1. INTRODUCTION
1.3 Runx family
RUNX proteins belong to the Runx family which is deeply involved in development regulation.
These transcriptional factors are characterized by a highly conserved Runt domain, first described
in Drosophila melanogaster (Gergen and Butler, 1988). This domain is located at the N-terminus
and contains 128 amino acids (Ito, 2004) that can specifically recognize the sequence PyGPyG-
GTPy (Py = pyrimidine) (Kamachi et al., 1990).
This family has three members: RUNX1, RUNX2 and RUNX3 (Figure 1.4). Research using the
mouse model revealed a non-redundant and tissue specific role for each of the Runx genes: runx1
knockout led to a lack of definitive hematopoiesis (Bee et al., 2010); no bone formation was observed
in the runx2 knockout (Komori et al., 1997) and runx3 knockout was associated with defects in
cytotoxic T cell development (Ito et al., 2008), neural and gastrointestinal disorders (Inoue et al.,
2002 and Li et al., 2002, respectively).
Figure 1.4: Structure of the RUNX protein family. The conserved Runt domain is responsible
for the recognition and binding of DNA. All members possess a Nuclear Matrix Targeting Signal
(NMTS) and a Nuclear Localization Signal (NLS); however, only RUNX2 includes a QA domain
containing a stretch of Glutamine and Alanine residues. Adapted from Camacho, 2011.
Although the Runt domain can recognize and bind to a specific DNA sequence, this protein-DNA
interaction can be increased and stabilized by CBFβ.
1.4 Core Binding Factor β (CBFβ)
CBFβ binds the Runt domain of all Runx family members and, besides enhancing its affinity to
DNA (Bartfeld et al., 2002; Nagata et al., 1999), it can also protect RUNX proteins from ubiquitin-
proteasome degradation (Huang et al., 2001). Interestingly, it was shown that CBFβ itself does
not bind the DNA directly (Nagata et al., 1999) and neither does it possess a nuclear localization
sequence (NLS, Blyth, Cameron, and Neil, 2005). Under which circumstances CBFβ is localized
in the nucleus is still poorly studied. However, despite the nuclear localization of CBFβ, it has
been reported by Meder et al. (2010) that CBFβ is also a structural protein of the sarcomeric
Z-disc, essential to maintain its functional structure. In different model systems, it has been shown
that genetic abnormalities in genes involved in mechanical Z-disc stabilization lead to heart failure,
stressing the need for detailed CBFβ research in this context.
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1.4.1 CBFβ loss-of-function models
In the zebrafish CBFβ loss-of-function model, heart function is impaired, with reduced heart rate
and fractional shortening (Meder et al., 2010). Furthermore, upon tactile stimulation, CBFβ
morphants showed weak or complete absence of skeletal muscle response. These findings were
consistent with the sarcomeric disarray observed in these morphants (Meder et al., 2010).
To better understand the phenotype of CBFβ null mutants both in mouse and zebrafish, it is crucial
to have a basic understanding of the hematopoiesis process. During embryonic development, several
waves of hematopoiesis occur in separate locations. The first wave is defined by the migration of
both the primitive myeloid progenitors (later differentiating into macrophages and neutrophils)
and erythromyeloid progenitors (later generating erythrocytes, mast cells and neutrophils) from
the anterior and posterior lateral mesoderm, respectively. In a second wave, the hematopoietic
stem and progenitor cells (HSPC) are formed in the dorsal aorta or aorta-gonad-mesonephros, in
mouse and zebrafish, respectively. The HSPC suffer an endothelial hematopoietic transition after
which they enter circulation and colonize several organs (Bresciani et al., 2014; Forrester, Berman,
and Payne, 2012).
In the mouse CBFβ null mutant (cbfβ-/-) the embryos showed a total lack of multipotent hemato-
poietic progenitors and died prematurely due to hemorrhages into the central nervous system
(Sasaki et al., 1996). Of note, cbfβ-/- showed a similar phenotype to runx1-/-. In both models,
the absence of definitive hematopoietic lineages suggests that both genes are necessary for HSPC
specification (Sasaki et al., 1996). Further studies in zebrafish could elucidate distinct functions
for CBFβ and RUNX1 (Bresciani et al., 2014). Bresciani et al. 2014 showed that RUNX1 is
necessary for the emergence of HSPC, while CBFβ is pivotal for the release of HSPC from the
aorta-gonad-mesonephros region in a later stage of development.
Until now, the function of CBFβ was analysed in early development by the characterization of
loss-of-function morphants (Meder et al., 2010). Understanding the phenotype of disease causing
CBFβ mutations in humans, might further elucidate CBFβ dependent mechanisms.
1.4.2 CBFβ associated diseases
Translocations in chromosome 16 have been found to produce a fusion protein between CBFβ
and smooth-muscle myosin-heavy-chain (MYH11). This CBFβ-MYH11 isoform has been associ-
ated with acute myeloid leukemia (Liu et al., 1993) and extensively studied. Less studied is the
contribution of CBFβ to cleidocranial dysplasia (Machol, Mendoza-Londono, and Lee, 2006), a
congenital disease characterized by skeletal defects. Mouse studies where CBFβ was ablated in
skeletal cells showed that CBFβ is necessary for bone ossification, chondrocyte and osteoblast
proliferation and maturation (Chen et al., 2014).
In the sarcomere, CBFβ is primarily encountered as a structural protein but, as described before,
it can also be found in the nucleus interacting with the RUNX proteins. The translocation of
CBFβ from the sarcomere to the nucleus was studied by Yoshida et al. (2005), who showed that
CBFβ is retained in the sarcoplasm through the interaction with the protein Filamin A (FLNA).
In which circumstances is this interaction disturbed to allow CBFβ translocation to the nucleus
and how it is regulated remains unclear.
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1.5 Filamin family
The cytoskeleton is an essential cell component determining cellular movement, shape, division and
signal transduction in response to the external environment. The defining activity of filamins is
the capacity to transform a population of non-linked F-actin filaments into a dynamic orthogonal
network (Wang and Singer, 1977).
The filamin family consists of three isoforms: filamin A (FLNA), filamin B (FLNB) and filamin C
(FLNC) (Figure 1.5). FLNA is ubiquitously expressed in all tissues. FLNB, with the exception of
retinal epithelium where it is highly expressed, is expressed at much lower levels but also ubiqui-
tously. FLNC is expressed in skeletal and cardiac muscle cells (Stossel et al., 2001 and Feng et al.,
2006). In human and mice, flna is located on the X chromosome, while flnb and flnc are located
on chromosome 3 and 7, respectively.
Figure 1.5: Structure of the filamin family proteins. Filamin comprise a highly conserved actin
binding domain (ABD), rod 1 and 2 domains composed of immunoglobulin-like repeats, flexible
hinges between repeats 15-16 and 23-24 and the self-association domain (D) (Stossel et al., 2001,
Nakamura, Stossel, and Hartwig, 2011).
Filamins contain an N-terminal actin binding domain (ABD), which is highly conserved between
actin binding proteins (Clark et al., 2009; Sawyer et al., 2009). This 30 kDa domain comprises
two calponin homology (CH) domains, required for F-actin binding (Bresnick, Warren, and Con-
deelis, 1990). The ABD is followed by a rod region of filamin repeat domains that adopt an
immunoglobulin-like (Ig-like) configuration. With a total of 58 nm contour length, the rod 1
domain encompasses 1 to 15 Ig-like repeats. With only 19 nm due to pairing of neighbouring
Ig-like repeats, rod 2 encompasses repeats 16 to 23 (Nakamura, Stossel, and Hartwig, 2011) and
it is separated from rod 1 by a hinge. Another hinge separates rod 2 from the C-terminal self-
association domain (encompassing Ig-like repeat 24). It is not fully understood if filamins can
form heterodimers, however the detection of FLNB and FLNC heterodimer was reported in in
vitro cross-linking assays (Himmel et al., 2003). While no evidence was shown or hypothesis
formed proposing the heterodimerization of FLNA and FLNC (Himmel et al., 2003), data indicates
that FLNA could heterodimerise with FLNB to compensate for dysfunctional FLNA homodimers
(Sheen et al., 2002).
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1.5.1 Filamin A (FLNA)
Filamin A, with approximately 280 kDa, consists of 2647 amino acids. It is composed of an N-
terminal actin-binding domain (ABD) and a long rod-like domain of 24 repeats discontinued by
two hinge domains (30 amino acid flexible loop). The ABD comprises two calponin homology
domains and the filamin repeat 24 functions as the homo-dimerization domain (Savoy and Ghosh,
2013).
Besides binding actin filaments, FLNA interacts with more than 90 different proteins from different
pathways, mainly through its rod 2 domain (Popowicz et al., 2006 and Nakamura, Stossel, and
Hartwig, 2011). Several studies suggest that FLNA modulates the subcellular localization of its
interacting partners, thus regulating multiple signalling cascades of different pathways (Camacho,
2011).
The interaction of FLNA with actin but also with other proteins, can be regulated through different
factors. Nakamura et al. (2011) summarized it into (1) mechanical forces, (2) phosphorylation,
(3) proteolysis, (4) competition between binding partners and/or (5) multimerization of partners.
Importantly, Savoy et al. (2013) highlighted the different functional roles of complete FLNA
located in the cytoplasm and cleaved FLNA shuttling to the nucleus. Depending on the location
of FLNA, defined by its protein length (cleaved or complete) and also possibly its interacting
partners, different signalling pathways are activated. All these are important factors to investigate
in the context of cardiomyopathies.
1.5.2 FLNA loss-of-function models
Filamin-deficient mice showed an incomplete septation of the heart outflow tract, atrial and ventric-
ular septal defects, small right ventricle, hemorrhages, thickening of the mitral valve and skeletal
fusion defects (Hart et al., 2006). This led to male lethality in embryonic stages. A different
FLNA loss-of-function model exhibit abnormal epithelial and endothelial organization, as well as
aberrant adherens junctions (Feng et al., 2006). This was accompanied by an abnormal cardio-
vascular aortic arch, a thickened and malformed outflow tract valve, septal and atrial defects and
also abnormal angiogenesis (Feng et al., 2006; Zhou et al., 2007). Likewise, in this model, embryos
died prematurely. Currently, all the FLNA loss-of-function models created have high embryonic
lethality, hindering studies throughout development until adulthood.
Curiously, no major heart defects were detected in FLNB (Zhou et al., 2007; Lu et al., 2007) or
FLNC (Dalkilic et al., 2006) loss-of-function models. Moreover, up to date, no FLNA loss-of-
function model in zebrafish have been described. In addition, examining the phenotype of FLNA
mutations in humans, will broaden our understanding of FLNA complex function.
1.5.3 FLNA associated diseases
A nonsense mutation was identified in FLNA and shown to hinder the migration of neurons to
the central nervous system in humans (Fox et al., 1998). Males with this mutation, occasionally
displayed aortic dilatation and died from massive hemorrhage during the neonatal period, while
the ones surviving until adolescent years died of abdominal aortic aneurysms. Females manifested
a high incidence of strokes, congenital heart defects such as patent ductus arteriosus and aortic
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aneurysms (Fox et al., 1998; Zhou et al., 2007). Multiple FLNA mutations were associated with
skeletal (such as otopalatodigital syndrome) and cardiac malformations that often lead to perina-
tal death. Kindt et al. linked FLNA mutations to familial cardiac valvular dystrophy (X-linked
myxomatous valvular dystrophy, Kyndt et al., 2007; Goodwin et al., 2012). Missense mutations
affecting the actin-binding site of FLNA which results in frontometaphyseal dysplasia, with ac-
companying extraskeletal features such as cardiac, tracheobronchial and urologic malformations
leading to perinatal death have also been reported (Robertson et al., 2006).
There are several hints for an impact of FLNA mutations on myocardial function, however this
hypothesis was never clearly investigated in heart failure.
1.6 CBFβ and FLNA interaction
As mentioned before, CBFβ is primarily encountered in the sarcomere, however is known that
it translocates to the nucleus to interact with RUNX proteins. This particularity of CBFβ to
translocate to the nucleus is of utmost importance given that CBFβ might act as a stress signal
transducer from the sarcomere to the nucleus. Progressively more evidence is provided about the
role of several Z-disc structural proteins that convey information from the Z-line to the nucleus,
therefore uncovering their intracellular signaling function in addition to their structural function
in the sarcomere (Knöll, Hoshijima, and Chien, 2002). Yoshida et al. (2005) showed that CBFβ
translocation is partially regulated by the interaction with FLNA, which retains CBFβ in the
sarcoplasm of HeLa cells.
CBFβ interacts with FLNA through the repeat 23, hinge 2 and the self-association domain (repeat
24). On the other hand, FLNA binds CBFβ between the residues 68 to 93 (Yoshida et al., 2005).
The interaction between FLNA and CBFβ was investigated in the context of osteoarthritis by
Johnson et al., 2012. The authors identified FLNA as an interacting partner by cross-linking kar-
togenin (KGN) to its potential cellular interacting partners. Curiously, KGN and CBFβ compete
for the same FLNA binding region. In essence, KGN binds FLNA and disrupts CBFβ interaction,
promoting CBFβ translocation to the nucleus and chondrogenesis stimulation (Johnson et al.,
2012).
It is important to consider that possibly any protein binding to the same region as CBFβ might
interfere with its binding to FLNA. In Supplement Table S1 known interaction partners of FLNA,
that bind the repeats 23 to 24, are listed.
In summary, a deep understanding of the FLNA interactome will elucidate one of the possible
mechanisms that regulate CBFβ translocation to the nucleus. Furthermore, it would be relevant
to explore the response of FLNA and its interacting partners to stress factors present in the context
of cardiomyopathies.
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FLNA is an actin-binding cytoskeletal protein, involved in different cellular and stress response
mechanisms. The correct functioning of FLNA is essential for cells demonstrated by several mal-
formations being associated with diverse human diseases. CBFβ was identified by our group as an
important gene in heart failure pathogenesis. In particular, CBFβ acts as a transcriptional factor
interacting with FLNA thereby regulating the expression of important heart failure-related down-
stream genes. FLNA functions has been proposed to act as a regulatory layer of CBFβ shuttling.
This project aims to assess the genomic and functional mechanism by which FLNA contributes to
heart failure.
Using zebrafish as a model system, the objectives of this research were as follows:
I Analyse embryonic heart function in a transient FLNA loss-of-function model.
II Establish CRISPR-CAS9 methodology for the generation of zebrafish knockout lines.
III Understand the role of FLNA in the progression of heart failure using a stable FLNA loss-of-
function model.
IV Define FLNA and CBFβ cellular localization in wildtype and understand if cardiac-relevant
stress affects CBFβ cellular localization.
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Materials
3.1 Equipment
The equipment used for the experiments in this thesis is listed in Table 3.1.
Table 3.1: Equipment.
Equipment Model Manufacturer
Embryos manipulation
Dual-Stage Glass Micropipette
Puller
PC-10 Narishige
Stereoscope MZFLIII Leica
Stereoscope camera DFC310 FX Leica
Inverted microscope DMIRB Leica
Inverted microscope camera DFC360 FX Leica
Microinjector FemtoJet4i Eppendorf
Incubator Heraeus Thermo Fisher Scientific
Imaging
Fluorescence microscope Axioskop 2 plus Zeiss
Fluorescence microscope Ni-E Nikon
Fluorescence microscope camera AxioCam MRc Zeiss
Confocal microscope DMi8 Leica
Luminescense imaging system Isogen Life Sciences Proxima
Molecular Biology
Centrifuge 5430R Eppendorf
Centrifuge 5417R Eppendorf
Table top centrifuge D-6015 Neolab
Table top centrifuge MiniStar VWR
Thermomixer Comfort Eppendorf
Vortex mixer Reax 2000 Heidolph
Heat plate RCT basic IKAwerke
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Equipment Model Manufacturer
Molecular Biology
Lateral shaker DuoMax 2030 Heidolph
Tube roller SU 1400 SunLab
Weighing scale CP142S Sartorius
Microwave NN-SD452W Panasonic
Electrophoresis chamber PerfectBlue Mini L Peqlab
Electrophoresis power supply EPS 301 Amersham Pharmacia Biotech
UV transilluminator UST-20S-8E Biostep
Digital graphic printer UP-D895 Sony
Spectrophotometer SmartSpec Plus BioRad
HistoCore Pearl Leica
HistoCore Arcadia H Leica
Microtome RM 2145 Leica
pH/mV bench meter pH 211 Hanna Instruments
Real-time PCR system ViiA 7 Applied Biosystems
Thermocycler Mastercycler ep gradient S Eppendorf
Thermocycler SimpliAmp Applied Biosystems
X-ray film processor Cawomat 2000 IR Wiroma
Spectrophotometer Nanodrop Lite Thermo Fisher Scientific
Fragment Analyser - Advanced Analytical Technologies
3.2 Buffers and solutions
All buffers and solutions used in the experiments that were not provided by the equipment/reagent
manufacturer can be seen in Table 3.2.
Table 3.2: Composition of buffers and solutions.
Name Composition
E3 buffer 5 mM NaCl
0.17 mM KCl
0.33 mM CaCl2
0.33 mM MgSO4
1 % methylene blue
Dent’s fixative solution 80 % methanol
20 % DMSO
Dent’s bleach solution 70 % methanol
10 % H2O2
20 % DMSO
PBS 1:10 dilution of 10X PBS (Gibco)
with dH2O
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Name Composition
PBT 1X PBS
0.1 % Tween-20 (Roth)
PBST 1X PBS
1 % Tween-20 (Roth)
TNN lysis buffer 50 mM Tris-HCl, pH 7.5
120 mM NaCl
0.1 % NP-40
TNN working buffer TNN lysis buffer
1 mM DTT
1 mM NaVO3
1 mM NaF
0.2 mM PMSF
1X Protease Inhibitor Cocktail Tablets (Roche)
1X PhosSTOP (Roche)
Deyolking buffer 55 mM NaCl
1.8 mM KCl
1.25 mM NaHCO3
Washing buffer 10 mM Tris-HCl, pH 8.5
110 mM NaCl
3.5 mM KCl
2.7 mM CaCl2
TBS buffer 50 mM Tris-HCl, pH 7.4
150 mM NaCl
TBST buffer 50 mM Tris-HCl, pH 7.4
150 mM NaCl
0.05 % Tween-20
Running buffer 25 mM Tris
192 mM Glycine
0.1 % SDS
Blotting buffer 19 mM Tris-HCl
144 mM Glycine
15 % Methanol
Blocking buffer TBST buffer
5 % Milk powder
or 5 % BSA
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Name Composition
LB medium 10g Tryptone
10g NaCl
5g Yeast extract
in 1L dH2O
3.3 Biological material
3.3.1 Zebrafish lines
All Danio rerio experiments were performed in accordance with the guidelines of the government of
Baden-Württemberg and have been approved by the Regierungspräsidium Karlsruhe (permit num-
ber 35-9785.81/G-1/15). The project involving genetically modified fish (number G-126/15) was
approved by the "Deutsches Zentrum zum Schutz von Versuchstieren". The AB strain (European
Zebrafish Research Center, ZDB-GENO-960809-7) was used as the wildtype reference.
3.3.2 Bacteria strains
One Shot TOP10 (Thermo Fisher scientific) bacteria strain with the following genotype: F- mcrA
∆ (mrr-hsdRMS-mcrBC) Φ 80lacZ ∆ M15 ∆ lacX74 recA1 araD139 ∆ (araleu)7697 galU galK
rpsL (StrR) endA1 nupG was used for TA and DNA Ligase cloning.
3.4 Ensembl genome browser IDs
DNA sequences were retrieved from the Ensembl genome browser 97, using the zebrafish genome
version GRCz11 (Table 3.3).
Table 3.3: Ensembl IDs used.
Gene
name Gene ID Transcript Name Transcript ID % similarity with human orthologues
flna ENSDARG00000074201 flna-202 ENSDART00000135820.3 82 %
cbfβ ENSDARG00000040917 cbfβ-203 ENSDART00000171871.3 81 %
flnb ENSDARG00000098374 flna-202 ENSDART00000164423.2 66 %
rplp0 ENSDARG00000051783 rplp0-201 ENSDART00000073462.5 90 %
Taken from http://www.ensembl.org. Last accessed 19th September 2019.
3.5 Oligonucleotides
3.5.1 DNA oligonucleotides
DNA oligonucleotide primers for gRNA cloning, PCR and qRT-PCR were obtained from Sigma
and are listed in Table 3.4 below.
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Table 3.4: Oligonucleotides.
Primer target Sequence Sense/Antisense Amplicon
CRISPR gRNA cloning
gRNA targeting
flna exon 2
5’ TAGGAAAGCCCTTGGCGCTCTGG 3’ Sense -
gRNA targeting
flna exon 2
5’ AAAGCCCTTGGCGCTCTGGGTTT 3’ Antisense -
CRISPR founders’ PCR screening
flna exon 2 5’ CCTGGGTCTGATATGGACTCTT 3’ Sense 276 bp
flna exon 2 5’ GGACCTATCAAACCCTGAGAAC 3’ Sense 276 bp
CRISPR off-targets’ PCR screening
ccdc22 5’ GCTCAGCAGGAAGCTGAACT 3’ Sense 459 bp
ccdc22 5’ GCAACCATGGACATTTTGAA 3’ Antisense 459 bp
nnt 5’ GACCGTGGACCACAAAAAGT 3’ Sense 544 bp
nnt 5’ CACATCAATCTTTGGCTGGA 3’ Antisense 544 bp
cnih2 5’ GGAGGAGGTTGCAGATTCTCT 3’ Sense 457 bp
cnih2 5’ AGCAGGGAGGAAGAACATGA 3’ Antisense 457 bp
caska 5’ TGCGCATAAAAACGATTGAT 3’ Sense 542 bp
caska 5’ TTTTGCCGTGTTTGTTTTCA 3’ Antisense 542 bp
smurf2 5’ GGAATGCAGCATCCAGAAAT 3’ Sense 446 bp
smurf2 5’ GGAATGCAGCATCCAGAAAT 3’ Antisense 446 bp
znf1140 5’ CTCAACCAAAAGGTTTCTCCA 3’ Sense 446 bp
znf1140 5’ AGTCCAACACCGTGATCCAT 3’ Antisense 446 bp
Clone sequencing
M13 5’ GTAAAACGACGGCCAGT 3’ Sense Variable
M13 5’ CATGGTCATAGCTGTTTCC 3’ Antisense Variable
qRT-PCR
flna 5’ CTGACAGCCACACTCACCAC 3’ Sense 80 bp
flna 5’ ATTCCCACATGCCCATTTCT 3’ Antisense 80 bp
cbfβ 5’ GACGGGAAAGGTGTACCTGA 3’ Sense 78 bp
cbfβ 5’ TGAAGATCAAGCCAGCCTCT 3’ Antisense 78 bp
flnb 5’ TACGGTCCAGGTATTGAGCC 3’ Sense 73 bp
flnb 5’ CACTGAACGTGTCCACAGTGA 3’ Antisense 73 bp
rplp0 5’ TGGAAAACAACCCAGCTCT 3’ Sense 75 bp
rplp0 5’ CTCCTTGGTGAAGACGAAGC 3’ Antisense 75 bp
3.5.2 Morpholinos
The morpholino (MO) modified antisense oligonucleotides were purchased from GeneTools, LLC.
All morpholinos were reconstituted in 200 mM KCl, pH 7.5 to a final concentration of 1 mM. The
MO targets, sequences and the titrated optimized concentrations can be found in Table 3.5.
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Table 3.5: Morpholino-modified antisense oligonucleotides.
Morpholino target Sequence Concentration
none 5’ CCTCTTACCTCAGTTACAATTTATA 3’ Variable
start-flna 5’ GTGTGTTGACTCATTTTTATCGACT 3’ 270 µM
start-cbfβ 5’ GACCACCCGAGGCATCTTGAACG 3’ 650 µM
3.5.3 Plasmids
The pT7-gRNA plasmid (46759, Addgene) was used to clone the gRNA for CRISPR gene editing.
The pCR4-TOPO (from the TOPO cloning kit, K457502, Thermo Fisher Scientific) was used to
clone PCR fragments for further Sanger sequencing.
3.6 Antibodies
Antibodies used for immunoblotting and fluorescent immunohistochemistry staining are listed in
Table 3.6 and Table 3.7.
Table 3.6: Primary antibodies.
Antibody target Host Concentration Blocking Catalog
number
Manufacturer
Immunoblotting
Anti-FLNA Rabbit 1:250,000 5 % filtered milk LS-B6554 LifeSpan
Biosciences
Anti-CBFβ Rabbit 1:500 5 % filtered milk ab33516 Abcam
Anti-TUBB Rabbit 1:500 5 % filtered milk ab6046 Abcam
Anti-GAPDH Mouse 1:500 5 % filtered milk H86504M Meridian
Sciences
Immunostaining
Anti-FLNA Rabbit 1:50 1X Power Block LS-C409442 LifeSpan
Biosciences
Anti-CBFβ Rabbit 1:50 1X Power Block ab33516 Abcam
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Table 3.7: Secondary antibodies.
Antibody target Host Concentration Blocking Catalog
number
Manufacturer
Immunoblotting
Anti-mouse,
HRP linked
Horse 1:3000 1X TBST # 7076 Cell Signalling
Anti-rabbit,
HRP linked
Goat 1:3000 1X TBST # 7074 Cell Signalling
Immunostaining
Anti-mouse
FITC
Goat 1:200 1X Power Block 1070-02 Southern
Biotech
Anti-mouse
TRITC
Goat 1:200 1X Power Block 1070-03 Southern
Biotech
Anti-rabbit
FITC
Goat 1:200 1X Power Block F1262 Sigma
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Methods
3.7 Zebrafish methods
3.7.1 Husbandry
Zebrafish maintenance and breeding was carried out as described byWesterfield (Westerfield, 1995).
Breeding and embryo maintenance
Sexually mature zebrafish were kept overnight in mating tanks, separated by a partition plate.
The partition was removed in the beginning of the light phase and spawning began shortly after.
Eggs were collected, rinsed and placed in a petri dish with 1X E3 buffer. Embryos were raised in
an incubator at 28.5 ◦C until 7 days post fertilization (dpf), upon which they were transferred to
the fish room system (Aqua Schwarz, Germany).
Adult maintenance
Adult zebrafish were maintained on a 14-hour light and 10-hour dark cycle at 28.5 ◦C in a recir-
culation system (Schwarz Ltd Germany, Mueller and Pfleger Ltd Germany). Mature fish were fed
daily with a combination of freshwater aquarium flake food (TetraWerke, Melle, Germany) and live
artemia shrimps (Sanders, Great salt lake, Artemia cysts). The care and treatment of the animals
were conducted in accordance with the guidelines established by the Seoul National University
Institutional Animal Care and Use Committee (Approval No. SNU-050418-2).
3.7.2 Embryo handling and manipulation
One-cell stage embryos were aligned in the grooves of injection ramps [in a petri dish, the mold
TU-1 (Adaptative Science Tools) was used to shape 3 % agarose (16500500, Invitrogen) in 1X
E3 buffer]. Prior to embryo injections, needles were created from 1 mm glass capillaries (World
Precision Instruments) using a glass micropipette puller at 68.3 ◦C and 70.1 ◦C temperature cycles.
Injections were done using a microinjector with a compensation pressure (Pc) of 15 hPa and an
injection time (ti) of 0.1 sec. The injection pressure (Pi) was adjusted for each needle. At 24 hours
post-fertilization (hpf) the 1X E3 buffer was replaced with 1-phenyl-2-thiourea (PTU; 0.2 mM) to
prevent melanization, thereby facilitating the imaging process.
Morpholino gene knockdown
Wildtype embryos were injected with a control morpholino-modified antisense oligonucleotide (MO)
in order to exclude unspecific toxic effects from a given injected concentration. The MOs were
complementary to the flna and cbfβ start site, therefore blocking translation. All MOs were
injected in one-cell stage embryos. Morpholino titrated optimized concentrations were injected as
described in Table 3.5.
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Isoproterenol exposure
Isoproterenol (ISO) is a non-selective beta adrenoreceptor agonist that is an analog of epinephrine
(adrenaline). All Isoproterenol (I6504, Sigma) dilutions were freshly prepared in 1X E3 buffer to
a final concentration of 1 mM. Embryos were incubated with 1 mM ISO for 100 min at 28.5 ◦C.
3.7.3 CRISPR gene knockout
Target site selection and gRNA production
Potential target sites were identified using the CHOPCHOP online tool (Montague et al., 2014,
Labun et al., 2016). A guide RNA (gRNA) targeting exon 2 of FLNA transcript 202 (Danio re-
rio GRCz11, ENSDART00000135820.3) was selected (sequence is listed on Table 3.4). The DNA
oligonucleotides were cloned into a pT7-gRNA plasmid via T4 DNA ligation cloning (1048122001,
Roche). The gRNA was produced using the in vitro transcription kit T7 MEGAshortscript
(AM1354, Thermo Fisher Scientific). Possible off-targets were determined with the CCTop tool
(del Sol Keyer et al., 2015) and primer sequences can be found in Table 3.4.
Embryo microinjections
The CRISPR-CAS9 (Clustered Regularly Interspaced Short Palindromic Repeats Associated Pro-
tein 9) protein (C15111835, ToolGen) was reconstituted in nuclease-free water to a final concen-
tration of 20 µM. The components were added to a 1.5 mL tube as follows: 1 µL of CAS9 protein,
1 µL of 750 ng/µL gRNA and 1 µL of 1 M KCl. The mixture was incubated at 37 ◦C for 20 min to
allow the protein and the gRNA to form complexes. The needle was calibrated using a calibration
slide (05A01040, Pyser-sgi) to a final injection volume of 1 nL. The embryos were aligned in the
injection ramps and the gRNAs were injected directly into the cell.
Genotyping and line propagation
Genotyping was performed in 24 hpf embryos or in adult zebrafish. Both embryos and adults were
exposed to tricaine methanesulfonate (E10521, Sigma-Aldrich) until there was no touch response.
In summary, the embryo or the adult fin was transferred to 100 µL of 50 mM NaOH and dissolved
rigorously at 95 ◦C for 20 minutes. The solution was neutralized by adding 10 µL 1 M Tris-HCl,
pH 8 and centrifuged at 14,000 for 15 min. The supernatant was used as a template for polymerase
chain reaction (PCR) as described in Section 3.8.1.
3.7.4 Embryo assessment
Embryo tissue harvesting
Embryos were immersed in concentrated tricaine methanesulfonate water and kept in this solution
for at least 10 min following cessation of opercular movement. In order to evaluate tissue specific
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gene or protein expression, as well as, the sarcomere structure; embryonic hearts were dissected
using a 0.5 nm needle. Embryo tail and head tissues were collected using forceps and scalpels.
Electron microscopy analysis
Embryos were immersed in concentrated tricaine methanesulfonate water and kept in this solution
for at least 10 min following cessation of opercular movement. Embryo skeletal muscle samples were
sent to the Electron Microscope Core Facility of Heidelberg University (EMCF). Sample processing
was performed by Charlotta Funaya, Steffi Gold and Sebastian Wurzbacher at the EMCF.
Phenotype analysis
To document embryos, these were anaesthetised with 0.02 % tricaine methanesulfonate. Embryos
were transferred to 2.5 % methylcellulose (64632, Fluka) dissolved in 1X E3 buffer and imaged
with a Leica MZFIII stereoscope. Video documentation was performed using the Leica DM IRB
inverted microscope with a 20X objective, at room temperature. For the latter, the software Virtual
Dub (version 1.7) was used to record 10 sec video frames of the beating heart. The heart rate
was determined by counting the heart beats in a period of 5 seconds and extrapolating to 1 min.
Fractional ventricular shortening was calculated by measuring the inner heart wall in the diastole
and the systole [using Fiji (Schindelin et al., 2012) and using the following formula: FS = (VEDD
- VESD) / VEDD * 100 % [FS - fractinonal shortening, VEDD - ventricle end-diastolic dimension
(pixels), VESD - ventricle end-systolic dimension (pixexls)].
3.7.5 Adult assessment
Genotyping
Adult zebrafish were genotyped by clipping the fin and extracting DNA using the NaOH protocol,
as mentioned in Section 3.7.3.
Behavioural analysis
Individual tanks containing adult zebrafish were transferred to the mating area and let to rest for
5 minutes. Zebrafish behaviour was assessed by determining the frequency of buccal movements
during three minutes (Jonz and Nurse, 2005).
Echocardiography (ECG)
The Vevo 2100 imaging system was used with the MS700 transducer to perform echocardiographies.
This transducer has 256 crystals displayed in a linear array that emitted waves with a frequency
between 30 and 70 MHz, reflected back from the zebrafish, hence allowing a visualization of the
different body structures, in particular the heart. Echocardiographies were performed in adult
zebrafish, with similar age and size. Echocardiographies were executed according to Hein et al.,
2015.
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Zebrafish dissection and tissue harvesting
Adult zebrafish were immersed in concentrated tricaine water until cessation of gill movement
could be observed. To excise the heart, the zebrafish were placed ventral side up in the groove of
a sponge under a dissecting stereoscope. In order to isolate the brain, the zebrafish were placed
ventral side down. The skeletal muscle and fin were removed with the zebrafish laying laterally.
3.8 Molecular methods
3.8.1 Polymerase chain reaction (PCR)
DNA was isolated from zebrafish embryos or adult fin using the NaOH protocol described in
Section 3.7.3. Polymerase chain reactions were performed using Taq Polymerase (201203, Qiagen)
and according to manufacturer’s instructions. Primers used are listed on Section 3.5.1.
3.8.2 Gel electrophoresis and gel extraction
To separate the DNA fragments by size, they were run on 1.0 % to 1.5 % agarose gels [(15510-0227,
Invitrogen) solved in 1X TBE buffer (A4686, AppliChem)]. Ethidium bromide (22182, Roth) was
added to the liquid agarose for later visualization of the bands. DNA loading dye (R0611, Thermo
Fisher Scientific) was added to a final concentration of 1X to each sample. The DNA fragment
size marker quick load 2-log DNA ladder (N0469, New England Biolabs) was added to the gel.
Negatively charged DNA fragments were separated using an electric current of 400 mA at 120
V for 90 min. Bands were visualized using a UV transilluminator (Biostep). Individual bands
were cut from the gel using a scalpel, DNA was extracted using the QIAquick gel extraction kit
according to manufacturer’s instructions (28706, Qiagen). Extracted DNA was stored in dH2O in
1.5 mL tubes at -20 ◦C.
3.8.3 RNA extraction
RNA was extracted from zebrafish embryos and adult tissues using miRNeasy Mini kit according to
manufacturer’s instructions (217004, Qiagen). The RNA quality and concentration was measured
using the fragment analyser (Advanced Analytical Technologies).
3.8.4 Reverse Transcription - quantitative PCR (qRT-PCR)
The Luna Universal One-Step RT-qPCR kit (E3005L, Biolabs) was used to analyse flna, flnb and
cbfβ mRNA expression level. For each reaction 100 ng of total RNA was used. The reaction
program used is listed in Table 3.8.
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Table 3.8: RT-qPCR reaction program using ViiA 7 from Applied Biosystems.
Stage name Temperature Time Transition Cycles
Hold stage 55 ◦C 20 s - 1
Reverse transcription 55 ◦C 10 min Increasing 2.63 ◦C/s 1
PCR cycle 95 ◦C 1 min - 1
95 ◦C 10 s -
- - Decreasing 2.42 ◦C/s 40
60 ◦C 30 s -
Melt curve 95 ◦C 15 s Decreasing 2.42 ◦C/s 1
60 ◦C 1 min Increasing 0.1 ◦C/s 1
95 ◦C 15 s - 1
3.8.5 Zebrafish protein extraction and quantification
To analyse the protein concentrations of FLNA and CBFβ in zebrafish, different tissues were
isolated as described in Section 3.7.4 and Section 3.7.5.
Protein extraction
Whole embryo For protein isolation of whole zebrafish embryos, 72 hours post-fertilization (hpf)
fish (n=30) were anaesthetised with 1 % tricaine methanesulfonate and collected in a 2 mL tube.
To remove the zebrafish yolk, embryos were washed with 1 mL deyolking solution. Then, the
embryos were washed with 1 mL washing buffer. Washing buffer was removed completely and
TNN working buffer was added (5µL per embryo added). Embryos were homogenized with 0.6
mm and 0.4 mm needles (300700, 302200, respectively, BD microlance 3). Embryo lysates were
incubated on ice for 15 min and centrifuged for 15 min at 14,000 rpm in a temperature-controlled
centrifuge at 4◦C. The supernatant was collected in a new 1.5 mL tube and stored at -80 ◦C.
Embryonic tissues A minimum of fifty 72 hpf embryonic hearts were collected per 2 mL tube.
Samples were centrifuged for 5 min at 14,000 rpm at 4 ◦C and the supernatant was removed.
1X Laemmli (161-0747, BioRad) diluted in TNN working buffer was added directly to the tubes.
The samples were boiled at 95 ◦C for 5 min. At this time point, samples could be stored at
-20 ◦C. After collecting a minimum of 50 embryonic zebrafish heads and 50 embryonic zebrafish
tails in Precellys tubes containing 1.4 mm ceramic beads (Precellys lysing kit, KT03961-1-009.2,
Precellys), the samples were centrifuged for 5 min, 14,000 rpm at 4 ◦C and the supernatant was
removed. 150 µL of TNN working buffer was added to each sample and samples were homogenized
using the Precellys mill (program: 2x 5,000 rpm 20 s, 10 s pause). Samples were incubated on ice
for 15 min and centrifuged for 15 min, 14,000 rpm at 4◦C. The supernatant was collected in a new
1.5 mL tube and stored at -80 ◦C.
Adult tissues For protein isolation, Precellys tubes containing 1.4 mm ceramic beads (Precellys
lysing kit, KT03961-1-009.2, Precellys) were used. Following the addition of 150 µL of TNN
working buffer to each sample, these were homogenized using the Precellys mill (program: 2x
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5,000 rpm 20 s, 10 s pause). Samples were incubated on ice for 15 min and then centrifuged for 15
min, 14,000 rpm at 4◦C. The supernatant was collected in a new 1.5 mL tube and stored at -80◦C.
Bradford protein assay
A Bradford assay was performed to measure sample protein concentration. According to Pierce
Coomassie (Bradford) protein assay kit instructions (23200, Thermo Fisher Scientific), 2 µL of
protein sample were added to 998 µL of 1X Bradford solution (diluted with dH2O). Sample ab-
sorbance was measured at 595 nm wavelength using a spectrophotometer (BioRad). Total protein
concentration was extrapolated from a comparison with the standard curve (previously created
using defined BSA samples diluted in TNN working buffer).
3.8.6 Western blot
Proteins were separated by SDS-PAGE (Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophore-
sis) using precast gels (456-1094, BioRad). Proteins were transferred to a polyvinylidene fluoride
(PVDF) membrane by wet blotting. The membranes were blocked in 5 % filtered (40 µm sterile,
542040, EASYstrainer, Greiner bio-one) milk dissolved in 1X TBST for at least 1h. These were
incubated in 50 mL falcon overnight at 4 ◦C with primary antibody (see Table 3.6). To ensure
constant and uniform sample agitation the tubes were incubated overnight in a tube roller device
(SunLab). The membrane was washed three times in 1X TBST and incubated with horseradish
peroxidase (HRP)-coupled secondary antibody for 2 h at room temperature (see Table 3.7). Pro-
teins bound by HRP-coupled secondary antibody were visualized by the use of ECL (Enhanced
Chemiluminescence) substrate (32106, Thermo Fisher Scientific). For low abundance proteins a
high sensitivity ECL substrate was used (GERPN2235, Merck).
3.8.7 Immunohistochemistry
At 72 hpf, embryos were collected in a 2 mL tube and fixed in Dent’s fixative (see Table 3.2)
overnight at room temperature. The next day, the embryos were transferred to Dent’s bleach (see
Table 3.2) and incubated overnight at room temperature. At this time point, the samples could
be stored in 100 % methanol or alternatively, the dehydration protocol could be followed directly
(see below).
Dehydration and paraffin embedding
The previously fixed and bleached embryos were transferred to a cassette (One-Piece Microbiopsy
Cassettes, 3802751, Leica). Using the HistoCore Pearl, the embryos were dehydrated and embedded
as described in Table 3.9.
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Table 3.9: Dehydration and paraffin embedding protocol. All steps were performed under pressure
and vacuum conditions to ensure enough tissue penetration by the reagents.
Solution Time Temperature
70 % ethanol 30 min 40 ◦C
80 % ethanol 30 min 40 ◦C
95 % ethanol 45 min 40 ◦C
100 % ethanol 45 min 40 ◦C
100 % ethanol 45 min 40 ◦C
100 % ethanol 45 min 40 ◦C
Xylene 45 min 40 ◦C
Xylene 45 min 40 ◦C
Paraffin 1 h 65 ◦C
Paraffin 1 h 65 ◦C
Paraffin 1 h 65 ◦C
Using the HistoCore Arcadia H paraffin machine, the embryos were aligned and the paraffin was
let to solidify in the cold plate for 10 min. The paraffin blocks were stored overnight at -20 ◦C.
The blocks were cut into 5 µm histological sections using the microtome (Leica). Histological slices
were added to microscope slides (1000200, Marienfeld) and dried on a hot plate (Hl1220, Leica)
for at least 2 hours (h) at 37 ◦C. The samples were stored at room temperature.
Fluorescent immunostaining
Paraffin was removed from specimens by washing with ethanol as follows: 2 x 5 min Xylene (534056,
Sigma), 2 x 5 min 100 % ethanol (603-002-00-5, Zentralbereich), 5 min 96 % ethanol, 5 min 70 %
ethanol, 5 min 1X PBS. After unmasking the antigens (2 x 5 min in the microwave at 1000 W, with
0.01 M Sodium Citrate pH 8.0 adjusted with 1 M NaOH) the slides were washed 2 x 5 min in 1X
PBS and 2 x 5 min in 1X PBST. The tissue sections were encircled with an ImmEdge hydrophobic
barrier pen (H-4000, Vector Labs). To reduce nonspecific binding sites, the slides were incubated
with 1X Power Block (HK 085-5K, Biogenex) for 30 min at 4◦C. The samples were incubated with
the primary antibody (1:50 in 1X Power Block) at 4 ◦C in the humidity chamber, overnight. The
slides were washed 3 x 2 min 1X PBS, with lateral shaking. In case of a double staining, the second
primary antibody (1:50 in 1X Power Block) was added and samples were incubated overnight at
4 ◦C in a in-house made humidity chamber. The slides were washed 3 x 2 min 1X PBS and then
incubated with the secondary antibody (1:200 in 1X Power Block) for 2 h at 4 ◦C. In case of a
double staining, both secondary antibodies were diluted in the same solution. The slides were
washed 3 x 2 min 1X PBS, with lateral shaking. In order to reduce the unspecific background
signal, slides were treated with the Vector TrueVIEW autofluorescence quenching kit (VEC-SP-
8400, Vector). For DAPI (4’,6-diamidino-2-phenylindole) staining samples were incubated with 1
µg/mL Hoechst (H3570, Thermo Fisher Scientific) for 10 min. After washing 2 x 2 min with 1X
PBS, the sections were covered with mounting medium (included in the Vector TrueVIEW kit)
and documented using a 40X objective (Numerical Aperture of 0.95 and a working distance of 0.23
- 0.17 mm) from the Nikon Ni-E motorized high-end upright microscope (at the Nikon Imaging
Center, core facility for light microscopy at the University of Heidelberg, Germany). The filter
cubes used can be visualized in Table 3.10.
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Table 3.10: Filter cubes used in the Ni-E microscope, with the 40 X Nikon objective.
Filter Excitation Wavelength Dichroic Mirror Emission Wavelength
DAPI 390 nm 416 nm 460 nm
EGFP 472 nm 495 nm 520 nm
TRITC 543 nm 562 nm 593 nm
3.8.8 Cloning
Topo TA
For a clear single peak Sanger sequencing result, PCR products were cloned into a pCR4-TOPO
TA Vector using the TOPO TA cloning kit (450071, Thermo Fisher Scientific) following the manu-
facturer’s instructions. Plasmids were transformed in Escherichia coli One Shot Top10 chemically
competent cells (C404010, Invitrogen) and plasmids were extracted using the plasmid miniprep kit
(732-2780, Peqlab).
T4 DNA ligase cloning
To incorporate the gRNA into a vector suitable for in vitro transcription, T4 DNA Ligase (10 487
220 001, Roche) was used. As in TOPO TA cloning, plasmids were transformed in E. coli One
Shot Top10 chemically competent cells (C404010, Invitrogen) and plasmids were extracted using
the plasmid miniprep kit (732-2780, Peqlab).
3.8.9 Next generation sequencing
For heart transcriptome analysis, RNA was collected from zebrafish adults and embryos as de-
scribed in Section 3.8.3. Regarding embryonic material harvesting, 300 whole embryos were pooled
per condition and 500 hearts were also pooled per condition. Adult samples were not pooled, each
sample represents one individual heart. The samples description can be found in Table 3.11.
FLNA knockout adult samples origin can be understood with help from Figure 4.10. Sequencing
was performed with IlluminaHiSeq 2000, using the TruSeq SBS Kit v3 (FC-401-3001, Illumina)
and reading 2x 100 bp for paired-end sequencing, on five lanes of a sequencing flow cell.
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Table 3.11: Total RNA sequencing samples from embryos FLNA knockdown and adult FLNA
knockout. Quality is measured in terms of RNA Quality Number (RQN) score and ranges from 1
to 10 (1 being low-quality and 10 being high-quality RNA).
Sample description Sample ID Concentration (ng/µL) RQN score
Whole embryos
Wildtype 10722 27.65 9.5
FLNA knockdown 10721 17.69 9.8
Embryonic hearts
Wildtype 10722 3548.38 9.3
FLNA knockdown 10721 1540.94 10.0
Wildtype controls - Adult hearts
Male 1 10484 19.99 9.0
Male 2 10485 26.65 8.3
Male 3 10486 25.21 7.9
Female 1 10487 41.78 6.2
Female 2 10488 23.77 8.0
Female 3 10489 15.61 8.1
Female 4 10490 22.49 7.4
Female 5 10491 22.87 8.2
Line 1 - Adult hearts
I:2 13890 7.13 1.5
II:3 13892 15.25 8.9
III:3 13893 6.71 8.5
Line 2 - Adult hearts
I:2 13894 11.86 8.1
II:4 13895 18.11 8.0
III:3 13897 18.46 8.1
3.9 Statistical analysis
Statistical analysis was conducted with GraphPad Prism 5 Software (GraphPad software, Inc.,
USA). All group data are presented as mean ± standard deviation (SD). Two-group comparisons
were made using Student’s t-test. If the data had a Gaussian distribution the unpaired t-test was
performed, otherwise the Mann-Whitney test was used. Null hypothesis was rejected at *p<0.05
(higher significance levels were denoted by **p<0.01 or ***p<0.001).
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4.1 CBFβ and FLNA transient loss-of-function model
To elucidate the function of FLNA and CBFβ, different transient gene knockdowns in piscine
embryos were established.
4.1.1 FLNA and CBFβ protein domains are highly conserved between human
and zebrafish
Considering that gene and protein conservation between humans and zebrafish is key to be able
to draw a significant parallel between the two organisms, both human and zebrafish amino acid
sequences were aligned.
Taken the amino acid sequence into account, zebrafish and human CBFβ share 86% similarity,
with a highly conserved domain (Figure 4.1 - A). The complete amino acid (Supplement Figure
S1) alignment between human and zebrafish can be seen in Section 6.
At the protein level zebrafish FLNA has 85% similarity to human FLNA, showing high conservation
within the domains (Figure 4.1 - B). The complete amino acid (Supplement Figure S2) alignment
between human and zebrafish is included in the Section 6.
Given the homology between human and zebrafish of FLNA and CBFβ, it is plausible to hypoth-
esize that their function is conserved in humans and proceed with the studies using zebrafish as a
model organism.
4.1.2 CBFβ knockdown leads to a heart failure phenotype
As previously described by our research group, translational blockade of CBFβ led to a heart failure
phenotype in zebrafish embryos (Meder et al., 2010). Compared with the morpholino-injected
control (MO-control) precardial edema (Figure 4.2 - A *), blood regurgitation from the atrium
to the sinus venosus (Figure 4.2 - A), a reduced heart rate (MO-control vs MO-cbfβ; mean±SD:
148±6.9 vs 108±22.0 beats/min, respectively; p<0.01; Figure 4.2 - C) and a reduced ventricular
systolic function (MO-control vs MO-cbfβ; mean±SD: 64.7±4.0 % vs 27.9±14.3 %, respectively;
p<0.001; Figure 4.2 - D) were observed at 72 hours post-fertilization (hpf).
The knockdown was confirmed by Western blot (see Section 3.8.5, Figure 4.2 - B) using whole
embryo protein extracts.
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Figure 4.1: FLNA and CBFβ protein conservation across species. A - CBFβ protein with the
RUNX binding domain (RUNX BD). B - FLNA protein with the actin binding domain (ABD),
1 to 15 filamin immunoglobulin-like repeats, hinge 1 (H1), 16 to 23 filamin immunoglobulin-like
repeats, hinge 2 (H2) and the self-association domain (D). Zebrafish percentage similarity to the
human sequence shown under each corresponding domain. Amino acid alignments accomplished
by using CLC Main workbench (QIAGEN Bioinformatics).
Figure 4.2: Functional analysis of CBFβ knockdown at 72 hpf. A - zebrafish embryo whole body
and heart phenotype of injected morpholino control (MO-control) and injected cbfβ morpholino
(MO-cbfβ); V - ventricle, A - atrium. B - Western blot confirming CBFβ knockdown at protein
level. C - heart rate in beats per min of MO-control and MO-cbfβ. D - measured ventricular
fractional shortening of MO-control and MO-cbfβ. p<0.001 (**) and p<0.0001 (***).
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4.1.3 FLNA knockdown leads to systolic dysfunction
The FLNA knockdown (MO-flna) was performed by using a morpholino blocking the translational
start site ATG. FLNA knockdown lead to systolic dysfunction, defects in re-absorption of cardiac
matrix, a dilated atrium, blood regurgitation during ventricular contraction and maturation defects
shown by uncompleted heart looping (Figure 4.3 - A). The heart rate (MO-control vs MO-flna;
mean±SD: 148±6.9 vs 108±25.1 beats/min, respectively; p<0.05; Figure 4.3 - C) and ventricu-
lar fractional shortening (MO-control vs MO-flna; mean±SD: 64.7±4.0 vs 19.3±10.8 beats/min,
respectively; p<0.001; Figure 4.3 - D) were significantly reduced in morphants.
The knockdown was confirmed by Western blot (see Section 3.8.5, Figure 4.3 - B) using whole
embryo protein extracts.
Figure 4.3: Functional analysis of FLNA knockdown at 72 hpf. A - lateral view of zebrafish embryo
at 72 hpf either injected with morpholino control (MO-control) or with a morpholino specifically
blocking the translation start site of flna (MO-flna); V - ventricle, A - atrium. B - Western blot
confirming FLNA knockdown at protein level. C - heart rate in beats per min of MO-control and
MO-flna. D - measured ventricular fractional shortening of MO-control and MO-flna. p<0.05 (*)
and p<0.001 (**).
One of the most common non-specific effects of morpholino-mediated knockdown is the up-regu-
lation of tp53 gene. Next generation sequencing was used to analyse the transcriptome of FLNA
knockdown whole embryos and hearts (see Section 3.8.9). The expression of tp53 in morpholino-
injected control and FLNA knockdown were not significantly different (MO-control vs MO-flna;
mean±SD: 8.1±0.9 vs 9.7±0.9 normalized reads, respectively; non-significant; Figure 4.4).
Furthermore, taken into account the high similarity between flna and flnb, it was necessary to
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evaluate if flnb was compensating for the lack of flna. The expression of flnb was not significantly
different from the injected morpholino control (MO-control vs MO-flna; mean±SD: 7.9±1.5 vs
5.4±0.5 normalized reads, respectively; non-significant; Figure 4.4).
Figure 4.4: Expression of tp53 and flnb in wildtype and flna morphants. Values presented as
normalized read counts. Data shown as mean±SD, non-significant (ns).
Two different FLNA isoforms were detected by Western blotting and the isoforms present in several
wildtype tissues were further investigate. FLNA was detected in whole embryo, adult heart, adult
skeletal muscle (Skm) and adult fin tissues (Figure 4.5 - A). As FLNA antibody targets the self-
association domain in the C-terminal of the protein, the detected fragments correspond to the
whole FLNA protein (at approximately 270 kDa) and the cleaved fragment at the hinge 1 domain
(at approximately 100 kDa, Figure 4.5 - B).
Figure 4.5: Protein isoforms of FLNA in different zebrafish tissues. A - FLNA protein levels
detected with Western blot. B - scheme of the antibody binding and cleavage site. C - predicted
flna isoforms from Ensembl genome browser 97.
While transcript flna-202 is the 270 kDa detected FLNA fragment, none of the Ensembl genome
browser 97 annotated transcripts (Figure 4.5 - C and Table 4.1) has a corresponding protein
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predicted size that would explain the detected 100 kDa FLNA fragment.
Table 4.1: flna transcripts annotated in Ensembl genome browser 97. For each transcripts the size
in nucleotide (bp), amino acid (aa) and kilodaltons (kDa) is described.
flna-202 flna-204 flna-205 flna-201 flna-203
Transcript (bp) 8551 1058 864 757 726
Protein (aa) 2553 353 No protein No protein No protein
Protein (kDa) 270 37 - - -
Taken from http://www.ensembl.org. Last accessed 6th September 2019.
Furthermore, given the structural function of FLNA, the sarcomeric structure in embryonic skeletal
muscle was evaluated via electron microscopy. The analysis exposed no significant alterations in
the sarcomere structure (MO-control vs MO-flna; mean±SD: 1.8±1.5 vs 3.9±6.6 ratio of thick
filaments per sectioned sarcomeric unit, respectively; non-significant; Figure 4.6), with preserved
primary organization of thick and thin filaments, in addition to these bundles organization in
higher ordered sarcomeric units.
Figure 4.6: Skeletal muscle analysis at 72 hpf with electron microscopy. A - comparison between
skeletal muscle structures of injected morpholino control (MO-control) and injected flna morpholino
(MO-flna). B - plotted ratio of thick filaments per number of sarcomeric unit. Data shown as
mean±SD, non-significant (ns).
4.2 Stable FLNA knockout resulted in altered heart morphology
and heart failure
Morpholino induced FLNA knockdown is a transient method to evaluate gene function in embryos.
The loss of FLNA through a stable knockout allows deeper phenotyping and the follow-up of disease
progression and onset of symptoms also in adult fish.
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4.2.1 CRISPR pipeline was established in zebrafish
FLNA knockout was accomplished using the bacterial CAS9, CRISPR (clustered regularly in-
terspaced short palindromic repeats) technology. A single-stranded gRNA composed of a flna
targeting gene sequence followed by the PAM (protospacer adjacent motif) sequence was designed.
The gRNAs were designed to target flna exon 2 of transcript 202 using CHOPCHOP (Labun et
al., 2016). The gRNA was cloned into a pT7-gRNA vector and the RNA produced using an in
vitro transcription kit (Figure 4.7 - A). One cell stage embryos were injected with CAS9 protein
complexed with gRNA. At 24 hours post-fertilization (hpf), 10 embryos were collected, genomic
DNA extracted and the region of interest (ROI) analyzed for FLNA mutations (Figure 4.7 - B).
This analysis provided an estimate of mutation efficiency, allowing us to predict the number of
adults with genome-edited FLNA. The remaining alive embryos, were grown to adulthood.
At 72 hpf, the F0-injected embryos were screened, in detail, to define until which extent the
embryos exhibit signs of heart dysfunction. Interestingly, the F0 injected embryos showed a heart
failure phenotype, with a reduced heart rate (wildtype vs F0 embryos; mean±SD: 144.0±18.5 vs
106.2±12.8 beats/min, respectively; p<0.001; Figure 4.8 - A) and a reduced fractional shortening
(wildtype vs F0 embryos; mean±SD: 63.7±9.7 % vs 42.9±9.2 %, respectively; p<0.001; Figure 4.8
- B). These embryos were grown to adulthood and tested for flna mutations. After reaching three
months of age, adult mosaic fish were genotyped by clipping the fin, extracting the DNA with
the NaOH method (see Section 3.7.3). ROIs were amplified with subsequently DNA sequencing
(Figure 4.7 - C). Adult fish with a mutated flna allele were labelled as founders and outcrossed
with wildtype adults to propagate the mutated line.
Different F0 mosaic founders carry different mutations, which lead to different penetrance and
phenotypic outcomes. As expected, the phenotype varied greatly between F0 founders. The heart
morphology and function of the F0 founders was analyzed with echocardiography (Figure 4.8 -
C). F0 adults showed an approximately normal ventricular ejection fraction, but compared with
the wildtype, also exhibited bradycardia and reduced velocity time integral (VTI). Mitral valve
regurgitation due to the lack of coaptation as a result of the heart chambers’ dilatation was also
detected. Taken together, these parameters indicate a heart failure phenotype.
To establish one mutation per individual fish, the F0 adults were outcrossed with wildtype (giving
rise to the F1 generation). F1 embryos were grown to adulthood and genotyped for mutations
in the targeted area of flna (Figure 4.9 - A). The F1 generation consisted of 52 fish carrying
different flna mutations. Since it was not feasible to propagate all these mutated fish lines, the
fish were categorized in terms of flna knockout efficiency at mRNA and protein levels, as well as
behavioural discrepancies. Overall, compared with wildtype, there was a significant reduction in
flna transcript levels for most of the F1 founders (wildtype vs F1 founders; mean±SD: 119.7±38.9
vs 35.1±23.2-fold change, respectively; p<0.001; Figure 4.9 - B). At the protein level, not all
individuals showed such an obvious difference compared to wildtype, which simplified selecting
which mutated fish lines to propagate (Figure 4.9 - C). To add another layer of information,
within the fish exhibiting reduced flna mRNA and FLNA protein levels, only the adults showing
the highest levels of hyperventilation were selected (wildtype vs F1 founders; mean±SD: 7.3±4.2
vs 64.1±39.0 buccal movements, respectively; p<0.001; Figure 4.9 - D, E). To clear the genetic
background of unwanted and unspecific mutations, two of the most promising F1 founders lines
were propagated through outcross with wildtype, to generate an F2 generation. The process was
repeated again to create an F3 generation.
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Figure 4.7: CRISPR line generation pipeline. A - design of a gRNA targeting flna exon 2,
incorporation of the gRNA sequence into pT7-gRNA plasmid and in vitro transcription to produce
the injectable gRNA. B (top) - one cell stage embryo injection of gRNA complexed with CAS9
protein, test of mutagenesis efficiency at 24 hpf and raise of the injected generation until adulthood.
B (bottom) - the localization of the mutagenesis screening primers (in red) is shown in the schematic
of the canonical zebrafish flna transcript. An example of the obtained Sanger sequencing results
for the mutagenesis screening at 24 hpf is shown for an unedited flna exon 2 and an edited flna
exon 2. C (top) - upon reaching adulthood, fin DNA was extracted and a PCR of the region
of interest (ROI - flna exon 2) - was performed. C (bottom) - the PCR products were sent for
Sanger sequencing and an example of a wildtype adult and an genome-edited fish, with multiple
sequencing peaks per base is shown.
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Figure 4.8: CRISPR F0 generation analysis. A - heart rate (beats/min) of wildtype embryos
compared to F0 injected embryos at 72 hpf. B - ventricular fractional shortening (%) at 72 hpf
of wildtype embryos compared to F0 injected embryos. C (left) - a schematic illustration of an
echocardiography linear transducer and specimen. C (right) - a representative example of the
echocardiogram results obtained from a wildtype adult and a mosaic F0 adult [top - pulse-wave
imaging shows mitral valve regurgitation (MVR); middle - heart morphology with the following
structures highlighted: bulbus arteriosus (BA), ventricle (V), lumen (L) and atrium (A) high-
lighted; bottom - table with the correspondent parameters weight (g), length (cm), heart rate
(beats/min, bpm), ejection fraction (%) and velocity time integral (VTI, mm)]. p<0.0001 (***).
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Figure 4.9: Assessment of CRISPR F1 generation. A - two representative examples of F1 founder
Sanger sequencing results compared with the wildtype flna reference sequence. B - flna expression
at mRNA level of wildtype adults compared to F1 founders [p<0.0001 (***)]. C - representative
western blot of FLNA protein levels of a wildtype and an F1 founder zebrafish. D - schematic of fish
gills illustrating oxygen exchange between ambient water and fish body (adapted from Taylor et al.,
2019). E - behavioural analysis depicting the ventilation frequency [number of buccal movements
in 3 min, p<0.0001 (***)].
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As mentioned before, F0 adults were outcrossed with wildtype to generate the F1 generation. The
F1 adults were analyzed as just described. Two F1 founders were selected for line propagation and
will from now on be addressed as lines 1 and 2.
Members of line 1 carry a 46 bp insertion that leads to a frame shift starting with a missense
mutation (c.606_607ins46; p.L203GfsX). The leucine (a neutral hydrophobic non-polar amino
acid) at position 203 was replaced with a glycine (also a neutral hydrophobic non-polar amino
acid). The frame shift is predicted to lead to a stop codon on exon 4 (Figure 4.10 - A).
Members of line 2 carry an 8 bp deletion, that also leads to a frame shift starting with a missense
mutation (c.605_612del8; p.A202DfsX). At position 202, the alanine (a neutral hydrophobic non-
polar amino acid) was replaced by aspartic acid (an negatively charged acid amino acid). With
the frame shift, it is predicted that a stop codon is introduced in exon 4, leading to a truncated
protein (Figure 4.10 - B). Both mutations, from line 1 and 2 are located in the actin binding
domain (ABD).
Parallel to raising lines 1 and 2, an incross between the F1 founders of these two lines was made.
The aim was to obtain a complete FLNA knockout and observe if a more prominent heart failure
phenotype would be provoked. These inbred lines (addressed as line 1U2) generated compound
heterozygous individuals, which had two distinct flna alleles carrying two separate mutations -
c.[606_607ins46; 605_612del8]; p.[L203GfsX; A202DfsX] (Figure 4.10 - C).
4.2.2 FLNA knockout was confirmed for the selected lines
To confirm the FLNA knockout, each line was genotyped and the flna mRNA expression and
FLNA protein levels analyzed.
Line 1 members harbor a 46 bp insertion, that could be clearly distinguished from the wildtype
by agarose gel electrophoresis [Figure 4.11 - B]. The individual bands were excised from the gel,
DNA was extracted and the PCR products cloned into a pCR4-TOPO vector. Samples were
sent for Sanger sequencing, by which the wildtype and mutated allele presence in this zebrafish
line could be confirmed [Figure 4.11 - A]. flna relative expression was significantly reduced in
all generations (wildtype vs line 1 founders; mean±SD: 100.0±15.1 vs 45.4±10.7-fold change,
respectively; p<0.001; Figure 4.11 - C). At the protein level, all individuals showed a reduction in
FLNA levels (Figure 4.11 - D).
Line 2 genotyping, with only 8 bp deletion, was harder to distinguish from the wildtype in an
agarose gel [Figure 4.12 - B]. Using a 3% agarose gel, the individual bands could be excised
separately, DNA was extracted and the PCR products cloned into a pCR4-TOPO vector. Samples
were sent for Sanger sequencing, by which the wildtype and mutated allele were confirmed [Figure
4.11 - A]. The relative expression of flna was significantly reduced in all generations (wildtype vs
line 2 founders; mean±SD: 100.0±15.1 vs 39.0±32.8-fold change, respectively; p<0.001; Figure
4.12 - C). Is noteworthy that even though all fish had the same genomic flna mutation, the mRNA
expression was distinct for each member. Furthermore, there seems to be a recovery of flna
expression for the F3 generation (Figure 4.12 - C). All individuals showed a reduction in FLNA
protein levels (Figure 4.11 - D), however not as pronounced as for line 1.
For line 1U2, the genotype of a compound heterozygous fish was confirmed by agarose gel elec-
trophoresis and Sanger sequencing (Figure 4.13 - A and B). Compared with the wildtype, a bigger
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Figure 4.10: FLNA knockout selected lines pedigree. A - line 1 with a 46 bp insertion leading to
a frame shift missense mutation, with a stop codon introduced in exon 4. B - line 2 with a 8 bp
deletion also causing a frame shift missense mutation, with a stop codon introduced in exon 4. C
- incross of line 1 and 2 producing a compound heterozygous with both flna alleles carrying a stop
codon on exon 4. These pedigrees are merely representative of the wildtype (wt), heterozygous
(het) and compound heterozygous (comp het) obtained for each line.
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Figure 4.11: Line 1 - FLNA knockout confirmation. A - representative example of flna wildtype
and mutated alleles by Sanger sequencing. B - genotyping confirmation with gel electrophoresis,
clearly illustrating the wildtype (WT) and mutated allele with insertion (ins) for a wildtype adult
(WT) and line 1 heterozygous (Het). C - flna relative expression analysis for all individuals of
line 1 [p<0.001 (**) and p<0.0001 (***)]. D - representative example of FLNA protein levels of a
wildtype and an heterozygous (Het).
Figure 4.12: Line 2 - FLNA knockout confirmation. A - representative example of flna wildtype
and mutated alleles by Sanger sequencing. B - genotyping confirmation with gel electrophoresis,
clearly illustrating the wildtype (WT) and mutated allele with deletion (del) for a wildtype adult
(WT) and line 2 heterozygous (Het). C - flna relative expression analysis, using qRT-PCR, for
all individuals of line 2 [p<0.001 (**) and p<0.0001 (***)]. D - representative example of FLNA
protein levels of a wildtype (WT) and an heterozygous (Het).
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PCR product, corresponding to the 46 bp insertion, and a smaller PCR product, corresponding
to the 8 bp deletion was detected. No FLNA protein could be detected as the FLNA antibody
cannot bind to either of the produced truncated FLNA proteins (Figure 4.13 - C).
Figure 4.13: Line 1U2 - FLNA knockout confirmation. A - representative example of both flna
mutated alleles by Sanger sequencing. B - genotyping confirmation with agarose gel electrophoresis,
illustrating the wildtype (WT) and both mutated alleles with a deletion (del) and an insertion (ins)
for a wildtype adult (WT) and line 1U2 compound heterozygous (Comp Het). C - FLNA protein
levels of a wildtype (WT) and the compound heterozygous (Comp Het).
4.2.3 No off-target effects were detected in FLNA knockout lines
To ensure a clear correlation between the mutated flna gene and the observed phenotype, outcross-
ing with wildtype fish was performed. By outcrossing F1, F2 and F3 the probability that the genetic
background remains wildtype while selecting for flna mutation carriers only is increased. This is
important because only flna mutation contribution to the phenotype is relevant to these studies.
Possible off-target mutations at the genomic level were predicted (see Section 3.7.3) and analyzed
via PCR and Sanger sequencing. At the transcriptomic level, wildtype and FLNA knockout line
members heart transcriptome was analyzed via NGS (see Section 3.8.9).
No CRISPR gene editing was visible in the analyzed potential off-target sites (Figure 4.14 - A)
and their mRNA expression was similar to wildtype adults (Figure 4.14 - B).
4.2.4 FLNA knockout lines exhibited a heart failure phenotype
The phenotype of FLNA knockout adults was analyzed using echocardiography, behavioural anal-
ysis and by characterization of external features.
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Figure 4.14: Predicted off-targets analysis for FLNA knockout lines. A - representative example
of predicted off-target alignment of the Sanger results (top to bottom - caska, ccdc22 and cnih2 ).
B - heart transcriptome analysis for wildtype and FLNA knockout lines; normalized read counts
for znf1140, cnih2, ccdc22, smurf2, caska and nnt [non-significant (ns)].
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Line 1 individuals had a wildtype phenotype in regard to external features, such as fins, pigmen-
tation and body shape (Figure 4.15 - A). Heart morphology naturally varies from individual to
individual. Nevertheless, an 73% of line 1 members showed an enlarged bulbus arteriosus lack-
ing the characteristic wildtype pear-shape. Enlarged ventricles were observed for 27% of line 1
members (Figure 4.15 - B). Heart rate was not affected in line 1 individuals (wildtype vs line 1
founders; mean±SD: 84.3±23.8 vs 100.2±27.6 beats/min, respectively; non-significant) but there
was a significantly reduced ejection fraction (wildtype vs line 1 founders; mean±SD: 61.2±6.9 vs
42.7±12.1 %, respectively; p<0.01; Figure 4.15 - C).
Figure 4.15: Line 1 - Adult heterozygous phenotype. Column A - representative examples of fish
morphology (top) and Pulsed-Wave Doppler (PWD) recordings, from which the heart rate and
velocity time integral were calculated (bottom). Column B - sagittal long axis view by B-Mode
imaging, depicting heart morphology and chamber relative position to each other; BA - bulbus
arteriosus, V - ventricle, A - atrium. Column C - measured parameters for both wildtype and FLNA
knockout line 1; weight (W), length (L), heart rate (HR), ejection fraction (EF) and velocity time
integral (VTI).
Line 2 individuals also showed an overall wildtype phenotype in regard to external features, however
I:2 developed a noticeable pericardial edema (Figure 4.16 - A). Furthermore, I:2 showed an altered
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pigmentation, probably due to the accumulation of blood in the pericardial area. The natural
variability of the heart morphology also holds true for line 2. Nonetheless, 67% of line 2 members
displayed an enlarged bulbus arteriosus. Moreover, 50% of line 2 fish had an enlarged ventricle
compared to wildtype (Figure 4.16 - B). Heart rate was not affected in line 2 individuals (wildtype
vs line 2 founders; mean±SD: 84.3±23.8 vs 102.9±27.6 beats/min, respectively; non-significant)
but there was a significantly reduced ejection fraction (wildtype vs line 2 founders; mean±SD:
61.2±6.9 vs 40.1±12.4 %, respectively; p<0.01; Figure 4.16 - C) for most of the fish. Surprisingly,
57% of the F3 fish showed a wildtype like ejection fraction.
Figure 4.16: Line 2 - Adult heterozygous phenotype. Column A - representative examples of fish
morphology (top) and Pulsed-Wave Doppler (PWD) recordings, from which the heart rate and
velocity time integral were calculated (bottom). Column B - sagittal long axis view by B-Mode
imaging, depicting heart morphology and chamber relative position to each other; BA - bulbus
arteriosus, V - ventricle, A - atrium. Column C - measured parameters for both wildtype and FLNA
knockout line 2; weight (W), length (L), heart rate (HR), ejection fraction (EF) and velocity time
integral (VTI). EF and VTI for individual I:2 should be critically analyzed.
The purpose of the incross between line 1 and line 2 was to generate a compound heterozygous
mutant. A stronger heart failure phenotype is expected from these individuals. The compound
heterozygous led to a stronger phenotype with a higher death rate during embryonic stages. In
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detail, only one compound heterozygous survived until adulthood (genotyping and FLNA protein
levels shown in Figure 4.13). Compared to wildtype, this fish was small, had an altered fin structure
and like fish I:2 from line 2, exhibited a noticeable pericardial edema. Once this individual died,
the heart was dissected (Figure 4.17 - A). This heart showed massively enlarged chambers, both
the ventricle and the atrium (Figure 4.17 - B). Furthermore, the blood accumulated outside of
the heart chambers, probably within the pericardial cavity, suggesting a pericardial hemorrhagic
effusion.
Figure 4.17: Line 1U2 - Adult compound heterozygous phenotype. A - dissected heart from a
wildtype fish in comparison to the dissected heart from the compound heterozygous fish from the
line 1 and 2 incross. B - chamber size ratio obtained by normalization of the chamber area to the
body length.
Taken together, throughout all FLNA knockout (FLNA KO) generations, the adult heterozygous
showed a tendency for reduced body weight (wildtype, mean±SD: 0.45±0.3 g; FLNA KO F1,
mean±SD: 0.61±0.15 g, non-significant; FLNA KO F2, mean±SD: 0.31±0.1 g, non-significant;
FLNA KO F3, mean±SD: 0.25±0.1 g, p<0.05) and length (wildtype, mean±SD: 3.3±0.3 cm;
FLNA KO F1, mean±SD: 3.7±0.4 cm, non-significant; FLNA KO F2, mean±SD: 3.4±0.2 cm,
non-significant; FLNA KO F3, mean±SD: 3.0±0.3 cm, non-significant; Figure 4.18 - A and B).
This reduction might be due to the fact that the F1 and F2 fish were kept exclusively in individual
1L tanks, while F3 fish were kept in a 15 L tank, allowing feeding with no competition. A correlation
between the FLNA knockout and the body weight and length was excluded.
As an indication for oxygen deprivation, the ventilation frequency was measured (number of buc-
cal movements in 3 min; Figure 4.18 - C). Hyperventilation in F1 and F2 adult heterozygous
fish was observed, while F3 coped better with the FLNA knockout in regard to oxygen depriva-
tion (wildtype, mean±SD: 6.3±3.0 buccal movements; FLNA KO F1, mean±SD: 24.0±5.7 buccal
movements, p<0.0001; FLNA KO F2, mean±SD: 17.5±6.4 buccal movements, p<0.0001; FLNA
KO F3, mean±SD: 10.0±3.4 buccal movements, p<0.001).
Albeit individually the lines showed no significant heart rate reduction, when an analysis per
generation was conducted, the heart rate was significantly increased for the F2, while the F1 and F3
remain not significantly different from the wildtypes (wildtype, mean±SD: 84.3±23.8 beats/min;
FLNA KO F1, mean±SD: 95.3±13.1 beats/min, non-significant; FLNA KO F2, mean±SD: 121.3±
14.1 beats/min, p<0.001; FLNA KO F3, mean±SD: 94.2±19.2 beats/min, non-significant; Figure
4.18 - D).
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The measured ejection fraction was significantly reduced for all generations, highlighting the heart
failure phenotype in FLNA knockout lines (wildtype, mean±SD: 61.6±7.8 %; FLNA KO F1,
mean±SD: 39.5±12.0 %, p<0.05; FLNA KO F2, mean±SD: 38.2±9.0 %, p<0.0001; FLNA KO
F3, mean±SD: 46.2±13.3 %, p<0.001; Figure 4.18 - E). Interestingly, there was an increase in the
SD (standard deviation) for the F3, accounting for the individuals with a wildtype-like ejection
fraction mentioned before. The velocity time integral was significantly reduced for F2 and F3,
ultimately reflected in the stroke volume and cardiac output (wildtype, mean±SD: 7.3±0.8 mm;
FLNA KO F1, mean±SD: 7.4±0.4 mm, non-significant; FLNA KO F2, mean±SD: 4.7±1.4 mm,
p<0.001; FLNA KO F3, mean±SD: 3.3±1.1 mm, p<0.0001; Figure 4.18 - F).
Figure 4.18: FLNA knockout heterozygous adults analysis by generation. A - body weight, in
grams. B - body length, in cm. C - zebrafish ventilation frequency analysis (number of buccal
movements in 3 min). D - heart rate, in heart beats per minute. E - ejection fraction, in %. F -
velocity time integral, in mm. non-significant (ns); p<0.05 (*), p<0.001 (**) and p<0.0001 (***).
4.2.5 Homozygous embryos exhibited a wildtype phenotype
To investigate the consequences of FLNA knockout during heart development, F3 adults from each
line were incrossed to generate F4 embryos. The only F3 male from line 2 was infertile. The out-
cross of line 2 F2 with wildtype was repeated to generate more F3 individuals. Nevertheless, the
experiment was performed using the F3 heterozygous adults from line 1. In the F4 generation, was
possible to identify wildtype, heterozygous and homozygous embryos (Figure 4.19 - A). According
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to Mendel’s laws of inheritance, 25 % wildtypes, 50 % heterozygous and 25 % homozygous is ex-
pected, which was approximately the ratios observed for FLNA knockout embryos (Figure 4.19 - B).
Phenotypically, the embryos exhibit a wildtype body shape and heart morphology (Figure 4.19 - C),
heart rate (wildtype, mean±SD: 123.0±18.0 beats/min; F4 heterozygous, mean±SD: 100.5±18.1
beats/min, non-significant; F4 homozygous, mean±SD: 108.0±12.0 beats/min, non-significant;
Figure 4.19 - D) and fractional shortening (wildtype, mean±SD: 45.8±9.2 %; F4 heterozygous,
mean±SD: 44.0±13.0 %, non-significant; F4 homozygous, mean±SD: 46.8±8.2 %, non-significant;
Figure 4.19 - E).
Figure 4.19: Line 1 - F4 embryos analysis. A - examples of the Sanger sequencing results for
wildtype, heterozygous and homozygous embryos. B - incross embryo count per genotype. C - 72
hpf wildtype, heterozygous and homozygous embryos phenotype; V - ventricle, A - atrium. D - 72
hpf heart rate according to genotype. E - 72 hpf fractional shortening (FS) according to genotype.
non-significant (ns).
4.2.6 Expression of flnb was up-regulated in FLNA knockout zebrafish
It was intriguing that the F3 incross yielded no heart failure phenotype embryos and that the
heterozygous adults from both lines showed a phenotype compared to the compound heterozygous.
Taken together, we hypothesised that an activation of compensatory mechanisms would lead to
such results. In the zebrafish genome as annotated, no flna paralogues were found. Considering
the filamin family, flnb expression was investigated in FLNA knockout lines.
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RNA was extracted from zebrafish hearts of each generation of line 1 and 2 and using next gener-
ation sequencing the heart transcriptoms were obtained (see Section 3.8.9). A significant increase
in flnb expression (Figure 4.20 - A) was detected. The expression of flnb was also analyzed in adult
fin by qRT-PCR. These findings could be validated for line 1 but not line 2 (wildtype, mean±SD:
1.0±0-fold change; line 1, mean±SD: 4.8±13.0-fold change, p<0.0001; line 2, mean±SD: 1.8±2.1-
fold change, non-significant; Figure 4.20 - B). However, analysing the Figure 4.20 in more detail,
it is possible to note that one individual (Figure 4.20 - B, arrow) has a high flnb expression (com-
parable to the flnb expression found in line 1 members). These results highlight the genetic and
phenotypic heterogeneity in zebrafish, indicating that each fish will have an individual response to
the FLNA knockout.
Figure 4.20: Expression of flnb in FLNA knockout lines compared to wildtype. A - heart tran-
scriptome analysis of adult heterozygous from each line. Shown normalized read counts for flnb
pooled per FLNA knockout line. B - fold change of the relative flnb expression for F2 founders of
each line. Highlighted is the line 2 outlier (arrow). non-significant (ns) and p<0.0001 (***).
4.3 CBFβ localization was affected by β-adrenergic stress
As shown above, loss of FLNA leads to heart failure by yet unknown mechanisms. To gain insights
into those, we used our model system described above to investigate if FLNA is a hub for CBFβ
and if stressors that are known to induce heart failure act via this interplay. In order to further
our knowledge regarding the interaction between CBFβ and FLNA their cellular localization were
determined. FLNA was mainly detected in the cytoplasm of zebrafish embryos (Figure 4.21 - A).
In wildtype conditions, CBFβ could also be detected in the cytoplasm. Furthermore, CBFβ is a
structural protein located at the Z-disc, thus stripes in the sarcomere can be observed (Figure 4.21
- B).
Using a FLNA knockdown model these previous findings were corroborated by showing an increase
of CBFβ in the nucleus, in the absence of FLNA (Figure 4.21 - C). In the wildtype setting, we strove
to understand if stress could influence the location of CBFβ. Given the cardiomyopathy context
of this thesis, β-adrenergic stress (through isoproterenol exposure) was investigated as a potential
trigger of CBFβ translocation to the nucleus. Interestingly, the translocation from the sarcomere
and cytoplasm to the nucleus did occur when the zebrafish embryos were under isoproterenol stress
(Figure 4.21 - D). The number of CBFβ enriched nuclei were counted and divided by the total
number of nuclei found in the section. These values were compared between wildtype, wildtype
53
CHAPTER 4. RESULTS
stimulated with isoproterenol (ISO) and FLNA knockdown. According to these results, 39% of
CBFβ translocated to the nucleus upon ISO stress, while 66% of CBFβ translocated to the nucleus
upon FLNA knockdown.
Figure 4.21: Immunostainings using histological slices of 72 hpf zebrafish embryos. A - location of
FLNA (green) in wildtype. B - location of CBFβ (green) in wildtype. C - CBFβ localization (green)
in FLNA knockdown (FLNA KD). D - CBFβ localization (green) in isoproterenol stimulated (ISO)
wildtype zebrafish. E - percentage of CBFβ enriched nuclei, using immunostaining data.
Finally, to visualise the cellular localization of FLNA and CBFβ upon stress in a schematic manner,
Figure 4.22 was created. In the next steps, different stressors in embryos and adults will be
investigated, in FLNA knockdown and knockout, respectively.
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Figure 4.22: Illustration of the cellular localization of FLNA and CBFβ. Muscle cell scheme with
cell membrane, cytoplasm, sarcoplasmic reticulum (SR) and nucleus represented. Adapted from
Chien, 2000.
55
5 | Discussion
In this thesis, the function of FLNA was investigated using a zebrafish knockdown and knockout
model. Our results showed that loss of FLNA, in both embryos and adults, resulted in a heart
failure phenotype.
A member of the filamin family, FLNC was already associated with cardiomyopathies. Two dif-
ferent FLNC variants were correlated with restrictive cardiomyopathy when patients display an
altered diastolic filling pattern and enlarged atria, but not with an abnormal systolic LV-function
and wall thicknesses (Brodehl et al., 2015; Tucker et al., 2017). It was also shown that FLNC
variants can result in hypertrophic cardiomyopathy derived from sarcomeric abnormalities and
formation of FLNC aggregates in muscle cells (Valdés-Mas et al., 2014). Moreover, in a recent
study a FLNC truncation variant was associated with dilated cardiomyopathy (DCM, Begay et
al., 2018).
Given the similarities between FLNC and FLNA, it is expected that these proteins are involved in
similar pathways. Hence, the role of FLNA in heart morphogenesis and function was thoroughly
investigated in this thesis. There are several reports of FLNA variants in humans which showed a
severe phenotype at different organ levels (Fox et al., 1998; Zhou et al., 2007; Kyndt et al., 2007;
Goodwin et al., 2012; Robertson et al., 2006). Patients with human periventricular heterotopia
exhibited congenital heart defects (Fox et al., 1998; Zhou et al., 2007), while patients affected by
frontometaphyseal dysplasia and otopalatodigital syndrome also displayed cardiac malformations
(Robertson et al., 2006; Goodwin et al., 2012). FLNA variants were further associated with familial
cardiac valvular dystrophy (Kyndt et al., 2007).
A point mutation, as reported for FLNC (Brodehl et al., 2015; Tucker et al., 2017; Valdés-Mas
et al., 2014; Begay et al., 2018), can have an extensive effect and might lead to heart failure.
Unfortunately, only 30% to 50% of genetic dilated cardiomyopathies can be resolved by genetic
testing because many of the DCM contributing genes remain unknown.
Phenotypic differences between the zebrafish FLNA transient knockdown and stable knockout
Discrepancies between morphant and mutant phenotypes have been reported (Rossi et al., 2015;
El-Brolosy and Stainier, 2017; El-Brolosy et al., 2019; Stainier et al., 2017). At 72 hours post-
fertilization (hpf), flna morphants and F0 CRISPR-injected embryos both showed a heart failure
phenotype, with reduced heart rate and reduced fractional shortening (see Section 4.1 and 4.2.1).
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However, the heterozygous F1, F2, F3 and homozygous F4 embryo generations exhibit none of
the heart failure symptoms. There could be three main reasons for these differences between the
knockdown and knockout lines: 1) the observed FLNA knockdown phenotype is due to unspecific
effects; 2) the FLNA knockout phenotype is due to off-target effects and 3) in the FLNA knockout
fish utilise compensatory mechanisms absent in the FLNA knockdown. These three reasons shall
be discussed in the ensuing paragraphs.
One of the most common toxic effects of morpholino-mediated knockdown which may account for
unspecific effects is the induction of cell death by activation of the p53 pathway (Robu et al.,
2007). Using next generation sequencing to analyze the flna morphants’ embryo transcriptome, no
differences in the normalized read counts of tp53, between the morpholino control and MO-flna,
could be detected.
Besides non-specific morpholino effects, the difference between morphants and mutants could also
be attributed to mutant off-target effects. Six predicted gene off-targets were analyzed in mutant
heterozygous adults and found to be unaffected (see Section 4.2.3). To comprehensively confirm
the absence of unpredicted off-target effects with higher confidence, a whole genome sequencing
analysis of each FLNA knockout line should be performed.
Up to date, multiple studies showed that phenotypic differences between morphants and mutants
could be due to compensatory responses occurring in knockout animals (Rossi et al., 2015). In line
with this data, an up-regulation of flnb was detected in different fish of line 1 and 2 that could
explain the embryonic wildtype phenotype and the mild FLNA knockout phenotype observed in
the heterozygous adults (see Section 4.2.6). A transcriptomic comparison between flna mutant and
morphants was also conducted to confirm the mutant specific flnb overexpression. In morphants,
flnb expression was not significantly different from the wildtype embryos. To further investigate the
hypothesized compensatory mechanisms, a proteomic analysis should be conducted to verify the
FLNB protein levels. FNLB protein levels in the mutant embryos and adults should be compared
to wildtype zebrafish and additionally, to the flna morphants, the latter of which should not exhibit
any compensation. Not all gene knockouts lead to an up-regulation of paralogues or same family
genes; thus, genes with a function similar to FLNA (such as cytoskeletal proteins) should also be
investigated as a possible alternative compensatory mechanism.
In conclusion, FLNA knockdown embryos showed a heart failure phenotype which was absent in
FLNA knockout embryos. We hypothesize that the differences between morphants and mutants
can be attributed to active compensatory mechanisms in the FLNA knockout lines.
FLNB as a compensatory gene in FLNA knockout lines
It has been reported that not every kind of DNA lesions was sufficient to trigger a compensatory
response (El-Brolosy et al., 2019). El-Brolosy et al. (2019) showed that alleles that fail to pro-
duce a transcript is not sufficient to lead to an up-regulation of known compensatory genes. It
was proposed that degradation of the mutant transcripts is the key to induce a transcriptional
adaptation response. Such a mechanism has been reported for the mt2 gene (Schuermann, Helker,
and Herzog, 2015). A mutation in mt2 exon 1 with high levels of nonsense-mediated mRNA decay
displayed a mild angiogenesis phenotype. However, when the mutant transcripts were ablated with
the use of an antisense-mediated knockdown, a much more severe phenotype emerged (El-Brolosy
and Stainier, 2017).
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FLNA knockout lines showed an overall reduction but not a complete ablation of flna expression
levels. Based on the NGS data, all generations of each FLNA knockout line showed an up-regulation
of cardiac flnb expression. Both filamins (FLNA and FLNB) share circa 90 % homology and
have the same function although FLNB expression is much lower expressed compared to FLNA.
Reported by Hu et al. (2017), loss of FLNA in mouse cartilage growth plate promotes FLNB
expression and vice versa. Curiously, FLNA and FLNB can form functional heterodimers and
stabilize the actin cytoskeleton. It was also suggested that this compensatory effect is cell-type
specific, once loss of FLNB in lymphoblastoid cells did not stimulate an increase in expression
of flna (Farrington-Rock et al., 2008). This emphasizes the need to study FLNA compensatory
mechanisms specifically in cardiomyocytes.
It was observed that in the zebrafish heart, loss of FLNA leads to an overexpression of flnb.
However, using qRT-PCR, different flnb expression levels within the same generation of line 2
individuals could be detected. A slight variation between individuals is expected due to naturally
occurring divergences combined with technical inaccuracies. This stochastic variation can also be
observed within the wildtype fish or within members of line 1. However, this natural variation does
not account for the flnb 3-fold expression level changes found in one of line 2 members compared
to the others (see Section 4.2.6). On the other hand, phenotypic heterogeneity could explain such
wide variations in expression.
The line 2 fish that showed an increased expression of flnb demonstrates a similar compensatory
mechanism to the one found in line 1. On the other hand, the other line 2 members, with wildtype
levels of flnb, have an alternative compensatory response to FLNA knockout. Possibly, instead of
a flnb overexpression, these individuals use an alternative compensatory gene or a different open
reading frame or nonsense-mediated alternative splicing. The latter is a known event in which
exons containing premature stop codons are skipped via alternative splicing (Hentze and Kulozik,
1999). Remarkably, the transcripts produced might escape the nonsense-mediated decay provided
that the exon skipped does not contain essential motifs or that the newly formed transcript does
not have a frame shift (Anderson et al., 2017). To study possible alternative flna transcripts found
in FLNA knockout line 2 members, nanopore long-read sequencing is recommended.
Genetic and/or environmental variations lead to fluctuations in gene expression, which can im-
pact the response mechanisms to loss-of-function mutations (Kasper et al., 2017). Like in humans,
distinct genetic and phenotypic heterogeneity was observed. The members of line 1 and one partic-
ular individual of line 2 have different genomic mutations while presenting a similar compensatory
mechanism. On the other hand, line 2 members with the same genomic mutation have discrete
compensatory mechanisms.
Dilated cardiomyopathy phenotype in zebrafish
Zebrafish has been extensively used in cardiovascular research for the identification and validation
of cardiomyopathy relevant genes (Vogel et al., 2009; Asnani and Peterson, 2014; Chen et al.,
1996; Sehnert et al., 2002; Stainier et al., 1996; Driever et al., 1996; Xu et al., 2002). Different
loss-of-function models were created for genes known to cause DCM in humans. Consistently these
studies showed that the embryonic DCM phenotype in zebrafish is characterized by a reduced
cardiac contractility and cardiac output, dilated ventricle and atrium, blood regurgitation from
the ventricle to the atrium and blood congestion in the sinus venosus (Vogel et al., 2009). In
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the FLNA transient knockdown model established, embryos showed similar results with reduced
cardiac contractility, dilated chambers and blood regurgitation.
In human DCM there are gene-specific abnormalities. The same is observed in embryonic zebrafish
DCM models; for example, the vinculin loss-of-function model exhibited impaired touch and flight
response while the desmin loss-of-function model showed bradycardia (Vogel et al., 2009). In
the FLNA transient loss-of-function model established in this thesis, besides the above mentioned
features, embryos showed bradycardia and defects in re-absorption of the cardiac matrix.
Characterization of the embryonic phenotype is a crucial first step in unravelling the function of
DCM relevant genes. However, embryos can only be investigated for a short time period and
the mechanisms in action between embryos and adults most probably differ. Moreover, different
techniques are available for the adult zebrafish such as swimming performance and drug tests
which are not well established in embryos. Accordingly, it was relevant to evaluate adult zebrafish
response to flna loss-of-function and a stable flna knockout line was created.
Up to date, adult zebrafish cardiomyopathy phenotype is characterized by changes in the heart
morphology, with enlarged ventricles, for both hypertrophic cardiomyopathy (HCM) and DCM
(Dvornikov, Tombe, and Xu, 2018). The described adult zebrafish DCM models are mainly char-
acterized by hypocontractility and systolic dysfunction (Dvornikov, Tombe, and Xu, 2018). Also,
in swimming performance test, fish with impaired cardiac function had a reduction in the maximal
swimming velocity, compared to controls (Dvornikov, Tombe, and Xu, 2018). At the cellular level,
the zebrafish HCM model showed reduced density and increased width of the isolated cardiomy-
ocytes (Ding et al., 2011), while DCM hearts mostly exhibited elongated ones.
FLNA knockout lines showed a significantly reduced ejection fraction and velocity time interval,
indicating a heart failure phenotype. Interestingly, F2 individuals displayed tachycardia which
might be an attempt to compensate for the low cardiac output. The cardiac output is the product
of the heart rate and the stroke volume (Young, 2010). Therefore, with reduced stroke volume
the heart rate is increased to boost the volume of blood pumped to the organs (Young, 2010;
Lymperopoulos, Rengo, and Koch, 2013). If the cardiac output is critically reduced for an extended
period of time, even after the hormonal systems and the sympathetic reflexes have reached their
maximum compensatory effects the progression of heart failure can not be counteracted (Young,
2010).
Our findings are consistent with previously described zebrafish DCM and heart failure phenotypes,
both in embryos and in adults. It would be of interest to investigate the transcriptional levels of
pathogenic cardiac remodelling genes, such as nppa, nppb, vmhc and slc8a1a (Dvornikov, Tombe,
and Xu, 2018). Further research should also be conducted to understand how FLNA knockout
adults perform under physical stress. Notwithstanding, to fully understand the extent of the
cardiomyopathy observed in FLNA knockout lines, these hearts should be characterized at the
cellular level.
β-adrenergic stimulation leads to CBFβ translocation to the nucleus
For the first time, β-adrenergic stimulation was identified as a stress factor inducing CBFβ translo-
cation to the nucleus. A central role of the adrenergic nervous system (ANS) is the maintenance
of a normal cardiac output (Kossack et al., 2017). When activated, the ANS increases heart rate,
cardiac contractility, accelerates cardiac relaxation, decreases venous capacitance and leads to a
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constriction of cutaneous arteries (Lymperopoulos, Rengo, and Koch, 2013). The ANS can be
activated by two catecholamine neurotransmitters, norepinephrine and epinephrine; which are de-
tected by cell surface adrenergic receptors (AR). Among the several types of adrenergic receptors,
the human heart contains all subtypes of βAR in different proportions (75-80% of β1, 15-18% of β2
and 2-3 % of β3). Upon activation of the cardiomyocyte β1AR and β2AR, the Gstimulatory coupled
protein triggers the adenylate cyclase to convert adenosine triphosphate (ATP) to cyclic adeno-
sine monophosphate (cAMP). cAMP-dependent kinase (PKA) are thus activated and are able to
phosphorylate different celullar targets. Among these targets are calcium channels, ryanodine re-
ceptors, phospholamban, hyperpolarization-activated cyclic nucleotide-gated channels, troponin I,
myosin binding protein-C and phospholemman (Lymperopoulos, Rengo, and Koch, 2013). Ulti-
mately, these events result in a significant increase in intracellular free Ca2+, leading to alterations
in cardiac muscle contractility. Furthermore, PKA can also phosphorylate the βAR which causes
a functional desensitization. This can also be achieved by specialized G-protein-coupled recep-
tor kinases (GRKs) that directly phosphorylate the βAR. β-arrestins bind to the phosphorylated
receptor, promote its decoupling from the G-protein and target it for internalization.
With the help of β-adrenergic stimulation, the healthy heart can recover and maintain the cardiac
output, such as during physical activity. On the other hand, an unhealthy heart with myocardial
dysfunction could lead to a pathological hyperactivation of this pathway, resulting in increased
cardiac toxicity culminating in an increased morbidity and mortality (Lymperopoulos, Rengo, and
Koch, 2013).
In summary, β-adrenergic stimulation is an essential adaptation mechanism in the heart which
needs to be fully understood. How this stimulation induced CBFβ translocation to the nucleus is
not clear. Nonetheless, different hypothesis can be postulated: 1) the interaction between FLNA
and CBFβ is disrupted by the calcium influx upon βAR activation; 2) FLNA and CBFβ can still
interact but FLNA cleavage is increased and together FLNA and CBFβ translocate to the nucleus
or, more likely, 3) a combination of the above two hypothesis.
Interestingly, it is known that PKA phosphorylates FLNA serine 2152 (located in Ig20, Peverelli et
al., 2018). This FLNA phosphorylation impacts its conformation, dismantling the autoinhibitory
structure formed between Ig21 and Ig19 when FLNA is not phosphorylated (Ithychanda et al.,
2015). Curiously, FLNA S2152 phosphorylation facilitates the binding to integrins (Chen, Kolahi,
and Mofrad, 2009), which might be relevant in a heart failure setting given the important role of
integrins in different remodeling processes after myocardial infarction (Chen et al., 2016). It is
thus conceivable that PKA-mediated FLNA phosphorylation might affect the ability of FLNA to
bind CBFβ.
A direct correlation of FLNA phosphorylation and the β-adrenergic pathway was proposed by
Pons et a. (2017), where phosphorylated FLNA serves as a scaffold that links cargo to endosomes,
thereby promoting efficient recycling of β2AR (Pons et al., 2017). Additionally, PKA activated by
other ligand-activated G-protein-coupled receptors, were shown to increase FLNA phosphorylation
of Ig domains 16-24 (Tirupula et al., 2015).
Furthermore, it is known that certain FLNA phosphorylations can inhibit calcium-dependent pro-
teases (CAPNs) cleavage (Savoy and Ghosh, 2013). FLNA hinge 1 and 2 are known to be targeted
by CAPNs (Zheng et al., 2014). It has been reported that upon activation of Wnt5a pathway, the
resulting downstream signaling cascade leads to an increased calcium release from the sarcoplas-
mic reticulum into the cytoplasm, thereby activating the CAPN (O’Connell et al., 2009). The
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activated CAPN cleaves FLNA into several fragments (O’Connell et al., 2009). In patients with
heart failure, Wnt5a is up-regulated, which might promote myocardial inflammation and fibrosis
(Abraityte et al., 2017). In a different context, Zheng et al. (2014) showed that in response to
hypoxic stress, calpain-cleaved FLNA is increased. Moreover, unlike the uncleaved FLNA form,
the cleaved FLNA fragments migrate together with their interacting partners to the nucleus and
activate the transcription of downstream targets (Savoy and Ghosh, 2013). High levels of hypoxic
stress are commonly found in late stages of hypertrophic and dilated cardiomyopathy.
As shown in Section 4.1, two different FLNA protein isoforms were detected in embryos and adult
tissues; the predicted 270 kDa protein and also a 100 kDa fragment. This pattern has been previ-
ously observed in several studies (Zheng et al., 2014; Sorimachi and Ono, 2012; O’Connell et al.,
2009; Abraityte et al., 2017; Savoy and Ghosh, 2013) and, using mass spectrometry, it was proven
that both bands are indeed FLNA protein (Johnson et al., 2012). Nonetheless, FLNA cleavage
status in cardiomyopathy patients is unknown and it would be interesting to investigate whether
changes in the cleavage dynamics can be observed and correlated with the patients phenotype.
In zebrafish, it would be engaging to study the FLNA phosphorylation status after β-adrenergic
stimulation and correlate it with FLNA cleavage status. If FLNA phosphorylation is increased,
it would be of value to understand how FLNA and CBFβ interaction is affected. Possibly, by
replacing FLNA serine 2152 with a phosphomimetic amino acid and performing immunoprecipita-
tion experiments it would be possible to assess if FLNA and CBFβ could still interact. Moreover,
analyzing FLNA and CBFβ nuclear and cytoplasmic localization, through protein fractionation,
would allow a more accurate quantification of the translocation.
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Filamin A (FLNA) is an actin-binding cytoskeletal protein, mainly responsible for creating actin
orthogonal networks. Additionally, FLNA interacts with multiple proteins and is therefore involved
in several cellular processes and stress response mechanisms. A vast amount of FLNA mutations
have been reported in humans and were even associated with cardiac malformations. Core Binding
Factor β (CBFβ) is a structural protein of the sarcomeric Z-disc, essential to maintain its functional
structure and thus essential for heart function. In different model systems, it has been shown that
genetic abnormalities in genes involved in mechanical Z-disc stabilization lead to heart failure. Up
to date, numerous genes are associated with primary cardiomyopathies but due to the individual
genetic and phenotypic heterogeneity, the disease penetrance and expressivity vary greatly. Defin-
ing the cellular and molecular mechanisms by which gene variants lead to genetic cardiomyopathies
will, ultimately, allow a finer understanding of the pathophysiology of heart failure.
This project was designed to assess the genomic and functional mechanism by which FLNA con-
tributes to heart failure. Furthermore, one of FLNA proposed functions was to act as a regulatory
layer of CBFβ shuttling, we sought to understand if a cardiac-relevant stress could interfere with
FLNA/CBFβ interaction.
A morpholino-mediated knockdown of flna in zebrafish significantly impaired the embryos heart
function. The observed morphant phenotype was not due to toxic effects of the morpholinos
(given that the expression of tp53 was not significantly elevated for the morphants) nor due to the
interference from FLNA highly homologous counterpart FLNB (shown by the wildtype expression
of flnb in the morphants). To elucidate the contribution of flna in adults, a stable flna knockout was
created using CRISPR-CAS9 technology. Heterozygous FLNA knockout adults displayed a reduced
ejection fraction and velocity time integral, indicating an impaired heart contractility and reduced
cardiac output. In these adults, the heart morphology was altered revealing enlarged chambers,
mainly the bulbus arteriosus and the ventricle. Differences between morphant and mutant embryos
were observed and attributed to activated compensatory mechanisms in the FLNA knockout lines,
through flnb overexpression. Off-target effects were mostly excluded given that the expression of
all the predicted off-targets investigated was unaffected in FLNA knockout fish.
In humans, the main regulator of cardiac output is the adrenergic nervous system. In a heart
failure setting, this pathway is overstimulated resulting in cardiotoxic effects. In zebrafish, it was
shown that chronic β-adrenergic stimulation could induce cardiac dysfunction. Thus, we decided
to investigate the localization of CBFβ upon such stimuli. Transduction of stress signals from the
sarcomere to the nucleus is crucial to ensure an appropriate cell response to stress. CBFβ has been
suggested as such a shuttling protein, but little is known about the stress factors that induce the
aforementioned translocation. For the first time, β-adrenergic stimulation was shown to induce
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CBFβ translocation to the nucleus.
Collectively, our results indicate that FLNA is essential for correct heart morphology and function.
Notably, the same genetic and phenotypic heterogeneity seen with human variants was also ob-
served for zebrafish FLNA knockout. Moreover, CBFβ, an essential sarcomeric structural protein
necessary for proper heart function, was shown to translocate to the nucleus upon β-adrenergic
stress. Further studies are needed to clarify the connection of both FLNA and CBFβ to heart
failure. These would provide further possibilities to modulate pathogenic pathways in the heart
and thereby potentially enabling the discovery of new therapies.
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Known interaction partners of FLNA, that bind the repeat 23 and the self-association domain, are
listed in Table S1.
Table S1: Filamin partners binding to the region from repeat 23 to repeat 24. Table adapted from
Nakamura, Stossel, and Hartwig, 2011.
Partner Binding site Significance References
Signalling
TRPP2 20-24 FLNA reduces the activity of strech-
activated ion channels
Sharif-Naeini et al.,
2009
MKK-4 21-23 Necessary for TNFα activation of SAPK Marti et al., 1997
Phosphorylation
SHIP-2 22-24 SHIP-2 membrane ruffles localization is de-
pendent on FLNA
Dyson et al., 2001
PAK1 23 FLNA regulates PAK1-induced cytoskeletal
reorganization
Vadlamudi et al.,
2002
LNK 19-23 Its interaction with FLNA possibly leads T-
cell activation
He et al., 2000
Proteolysis
Epithin 14-24 FLNA is essential for the epithin shedding Kim et al., 2005
PMSA 23-24 Regulates internalization of PMSA and its
enzymatic activity
Anilkumar et al.,
2003
Furin 13-24 FLNA is required for Furin trafficking Liu et al., 1997
Ion channels
Kv4.2 20-24 FLNA localizes Kv4.2 channel to filopodial
roots and enhances its current density
Petrecca, Miller,
and Shrier, 2000
Kir2.1 23-24 FLNA regulates surface expression of the
Kir2.1 potassium channel
Sampson, Leyland,
and Dart, 2003
HCN1 23-24 FLNA localizes HCN1 to specific neuronal
areas and modulates its channel activity
Gravante et al.,
2004
Transcription
p73α 20-24 FLNA inhibits p73α transcriptional activity
by retaining it in the cytoplasm
Kim, Park, and
Um, 2007
BRCA2 21-24 Interaction with FLNA is required for effi-
cient regulation of early stages of DNA repair
processes
Yuan and Shen,
2001
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Partner Binding site Significance References
Smad5 20-23 FLNA facilitates TGFβ-mediated SMAD
phosphorylation and nuclear transportation
Sasaki et al., 2001
Receptors
µ opioid H2-24 FLNA is required for agonist-induced recep-
tor down-regulation and functional desensi-
tization
Onoprishvili et al.,
2003
Insulin 22-24 FLNA interacts with insulin signaling to in-
hibit MAPK cascade
He et al., 2003
CCR2B 19-24 FLNA is required for efficient internalization
of the CCR2B receptor
Minsaas et al., 2010
Muscle development
Titin 22-24 FLNA binds to the titin Z2-Zis1 domain in
smooth muscle cells
Labeit et al., 2006
Others
Caveolin-1 22-24 Interaction with FLNA promotes caveolae-
mediated endocytosis and trafficking
Stahlhut and
Van Deurs, 2000;
Sverdlov et al.,
2009
Decorin 22-24 FLNA binds to the leucine-rich repeat region
of decorin
Yoshida et al., 2002
cvHsp 23-24 cvHsp interacts with FLNA in the human
heart and insulin-sensitive tissues
Krief et al., 1999
Presenilins 21-24 FLNA interacts with the presenilin loop re-
gions mutated in familial Alzheimer’s disease
Zhang et al., 1998
CBFβ protein alignment between human and zebrafish showed a highly conserved runx binding
domain (Supplement Figure S1).
Figure S1: Human and zebrafish CBFβ protein alignment. Highlighted are the runx binding
domain and the FLNA interaction region.
FLNA protein, with 86% similarity, is highly conserved between human and zebrafish (Supplement
Figure S2).
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Figure S2: Human and zebrafish FLNA protein alignment. Marked in the alignment are the several
FLNA domains: Actin binding domain (purple), Rod1 and 2 (blue) with its several Ig-like repeats
(red) and hinge region (green).
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Abbreviation Explanation
A Atrium
aa Amino acid
ABD Actin binding domain
ACTB Beta-actin
ADP Adenosine diphosphate
AHA American heart association
ANS Adrenergic nervous system
AR Adrenergic receptor
ARVC Arrythmogenic right ventricle cardiomyopathy
ATP Adenosine triphosphate
BA Bulbus arteriosus
bp Base pair
bpm Beats per minute
BRCA BRCA DNA repair associated
BSA Bovine serum albumin
Ca2+ Calcium ion
CaCl2 Calcium chloride
cAMP Cyclic adenosine monophosphate
CAPN Calpain
CAS CRISPR associated protein 9
CCR2B C-C motif chemokine receptor
cDNA Complementary DNA
CH Calponin homology domain
cm Centimeter
Comp Het Compound heterozygous
CRISPR Clustered regularly interspaced short palindromic repeats
D Self-association domain
DAPI 4’,6-Diamidine-2’-phenylindole dihydrochloride
DCM Dilated cardiomyopathy
Del Deletion
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
dNTP Nucleoside triphosphate
dpf Days post fertilization
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Abbreviation Explanation
DTT Dithiothreitol
ECL Enhanced chemiluminescence
EDTA Ethylenediaminetetraacetic acid
EF Ejection fraction
EGFP Enhanced green fluorescent protein
FCS Fetal calf serum
FITC Fluorescein isothiocyanate
FS Fractional Shortening
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GRK G-protein-coupled receptor kinase
gRNA guide RNA
h Hour
H2O Water
H2O2 Hydrogen peroxide
HCl Hydrochloric acid
HCM Hypertrophic cardiomyopathy
HCN Hyperpolarization activated cyclic nucleotide gated potassium channel
Het Heterozygous
Hom Homozygous
hpf Hours post fertilization
HR Heart rate
HRP Horseradish peroxidase
HSPC hematopoietic stem and progenitor cells
Ig Immunoglobulin
Ins Insertion
ISO Isoproterenol
kb Kilo base
KCl Potassium chloride
KD Knockdown
kDa Kilo Dalton
KGN Kartogenin
Kir Inwardly rectifying potassium channel
KO Knockout
L Length
L Liter
L Lumen
LNK Lymphocyte adapter protein
LVNC Left ventricular non-compaction
M Molar
mA Milli ampere
MAPK Mitogen activated protein kinase
MgCl2 Magnesium chloride
MgSO4 Magnesium sulfate
µg Microgram
µL Microliter
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Abbreviation Explanation
µM Micromolar
min Minute
MKK MAPK kinase
mL Milliliter
mm Millimeter
mM Millimolar
MO Morpholino
mRNA Messenger RNA
MW Molecular weight
MYBPC myosin binding protein C
MYH β Myosin heavy chain
NaCl Sodium chloride
NaF Sodium fluoride
NaHCO3 Sodium bicarbonate
NaVO3 Sodium metavanadate
NGS Next generation sequencing
NH4OH Ammonium hydroxide
NLS Nuclear localization signal
NMTS Nuclear matrix targeting signal
ns non-significant
OMIM Online mendelian inheritance in man
Pc Compensation pressure
Pi Injection pressure
PAGE Polyacrylamide gel electrophoresis
PAK P21 activated kinase 1
PAM Protospacer adjacent motif
PCR Polymerase chain reaction
PKA Protein kinase A protein
pmol Picomol
PMSA Prostate-specific membrane antigen
PMSF Phenylmethylsulfonyl fluoride
PTU 1-phenyl-2-thiourea
QA Glutamine-alanine repeat domain
qRT Quantitative real-time
RCM Restrictive cardiomyopathy
RNA Ribonucleic acid
ROI Region of interest
rpm Revolutions per minute
RQN RNA quality number
SAPK Stress-activated protein kinase
SD Standard deviation
SDS Sodium dodecyl sulfate
sec Second
SEM Standard error of the mean
SHIP Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase
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Abbreviation Explanation
Skm Skeletal muscle
SR Sarcoplasmic reticulum
ti Injection time
TGFβ Transforming Growth Factor Beta β
TNFα Tumor necrosis factor α
TNNT cardiac troponin-T
TPM1 α-tropomyosin
Tris Tris hydroxymethyl aminomethane
TRITC Tetramethylrhodamine
TRPP Transient receptor potential polycystic
TUBB Tubulin β
V Ventricle
V Volt
VTI Velocity time integral
W Watt
W weight
WT and wt Wildtype
% Percent
◦C Degree Celsius
Nucleotide code
Abbreviation Explanation
A Adenine
C Cytosine
G Guanine
T (or U) Thymine (or Uracil)
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Amino acid code
Abbreviation Explanation
G Glycine (Gly)
P Proline (Pro)
A Alanine (Ala)
V Valine (Val)
L Leucine (Leu)
I Isoleucine(Ile)
M Methionine (Met)
C Cysteine (Cys)
F Phenylalanine (Phe)
Y Tyrosine (Tyr)
W Tryptophan (Trp)
H Histidine (His)
K Lysine (Lys)
R Arginine (Arg)
Q Glutamine (Gln)
N Asparagine (Asn)
E Glutamic Acid (Glu)
D Aspartic Acid (Asp)
S Serine (Ser)
T Threonine (Thr)
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